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MECHANISMS UNDERLYING DISTINCT EGFR VERSUS FGFR-3 AND 
-1 DEPENDENCY IN HUMAN BLADDER CANCER CELLS 
 
Tiewei Cheng, M.D. 
Supervisory Professor: David J. McConkey, Ph.D. 
 
The epidermal growth factor receptor (EGFR) and fibroblast growth factor 
receptor (FGFR) are activated by gene amplification, mutation and 
overexpression in bladder cancer, which drives tumor development and 
progression. Both EGFR and FGFR inhibitors are currently being tested in 
clinical trials. However, bladder cancer (BC) cells show remarkably 
heterogeneous sensitivities to both inhibitors, and the molecular 
determinants of this heterogeneity are presently unclear. Therefore, in this 
study, using selective EGFR and FGFR inhibitors in BC cells, we 
demonstrated that FGFR3 and FGFR1 play largely non-overlapping roles 
in mediating proliferation and invasion in the distinct “epithelial” and 
“mesenchymal” subsets of human BC cells. Furthermore, we examined 
the sensitivities to FGFR3 and EGFR inhibition in a panel of human BC 
cells, and found that FGFR3 and EGFR dependency are mutually 
exclusive biological phenotypes controlled by PPARγ-FABP4 pathway.  
This study significantly extends and complements our knowledge of 
molecular mechanism that mediates growth receptor dependent 
proliferation in BC. 
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1.1. Fibroblast growth factor family and its receptors in cancer 
1.1.1. The FGF-FGFR signaling system 
FGFs. The fibroblast growth factor (FGF) family is composed of 18 ligands 
that bind to four homologous high-affinity fibroblast growth factor receptors 
(FGFR1-4) [1]. The ligands can be classified into 6 subfamilies based on 
sequence similarity: FGF1-2; FGF3, FGF7, FGF10 and FGF22; FGF4-6; 
FGF8, FGF17 and FGF18; FGF9, FGF16 and FGF20; and FGF19, FGF21 
and FGF23 [1]. There are also 4 “FGFs” that are numbered (FGF11-
FGF14) but are not assigned to any subfamilies. Although these ligands 
share similar amino acid sequence with the FGF family, they do not 
activate FGFRs and therefore are not generally grouped into the FGF 
family [2]. Typically, FGFs can be classified as intracrine, paracrine and 
endocrine ligands respectively. Intracrine FGFs are intracellular molecules 
independent of FGFR and they mediate the function of voltage gated 
sodium channels [3]. However, paracrine FGFs, which is the major type of 
ligand, regulates physiological and pathophysiological functions by binding 
with and activating FGFRs at cell surface [4]. Recently, FGF19, FGF21 
and FGF23 have been shown to function via endocrine route and are 
thought to medicate biological response via FGFRs. These ligands 
function over long distances, and are dependent on co-existence of klotho, 
a nuclear receptor binds to FGFRs to increase its binding affinity to 
specific endocrine FGFs, which then regulate vitamin D, bile acid, 
cholesterol, and glucose homeostasis [5]. 
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FGFRs. The FGF ligands function by binding to the FGFR family and 
activating it through an HSGAG dependent manner. So far, four receptors 
(FGFR1, FGFR2, FGFR3 and FGFR4) have been identified in this family. 
FGFRs are comprised of three extracellular immunoglobulin domains (D1, 
D2, D3), a single-pass trans-membrane domain and a cytoplasmic 
tyrosine kinase domain (Figure 1.1) [6]. A distinct character of FGFRs is 
the presence of an acidic, serine-rich sequence between D1 and D2 
domains, named the acid box. The D2 and D3 domains of FGFRs are 
required for ligand binding and are used to determine ligand specificity. 
However, the D1 domain and the acidic box are believed to play a vital 
role in receptor auto-inhibition. There are several FGFR isoforms 
generated by multiple mechanisms, and alternative exon splicing of the D3 
domain is the most important one. For instance, alternative splicing at the 
second half of the FGFR1-3’s D3 domain produces b and c (i.e. FGFR1b 
and FGFR1c) isoforms that carry out discrete FGF binding specificities 
(Figure 1.1) [7]. Specifically, b isoforms are generally produced in 
epithelial tissue while c isoforms are generated in mesenchymal tissue [8]. 
Therefore, the FGF family ligand-receptor binding specificity (Table 1.1) is 
partially mediated through the primary sequence differences among the 18 
FGFs and 7 FGFR isoforms that are produced by alternative splicing. The 
ligand-receptor binding specificity is also  
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Figure 1.1 FGFR structure and alternative splicing. a. The basic 
structure of the fibroblast growth factor (FGF) –FGF receptor (FGFR) 
complex comprises two receptor molecules, two FGFs and one heparan 
sulphate proteoglycan (HSPG) chain. b. Ligand-binding specificity is 
generated by alternative splicing of the Ig III domain. The first half of Ig III 
is encoded by an invariant exon (IIIa), which is spliced to either exon IIIb 
or IIIc, both of which splice to the exon that encodes the transmembrane 
(TM) region. Adapted from Turner N, Grose R, Nat Rev Cancer. 2010 
Feb;10(2):116-29 with the permission from Nature Publishing Group. 
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Table 1.1 FGF-FGFR binding specificity.  
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regulated by temporal and spatial expression patterns of FGFs, FGFRs 
and HSGAGs. 
HSGAG binding and FGF-FGFR dimerization and activation. A 
functional FGF-FGFR complex is comprised of two FGF-FGFR-HSGAG 
(on a 1:1:1 basis) symmetrical units [9]. HSGAG binds to a basic canyon 
at the distal end of the membrane to facilitate and bolster protein to protein 
interactions. Ligands, shuttled by FGF-binding protein that releases FGFs 
from the extracellular matrix [10], bind to both receptors, and the two 
receptors interact with each other through a subdomain at the base of D2 
[11]. HSGAG binding serves two primary purposes to promote the FGFR 
signaling. First, HSGAG promotes ligand-receptor dimerization by 
facilitating and strengthening protein-to-protein interaction between FGF 
and FGFR both inside and outside the complex through simultaneously 
binding to both ligand and receptor. Second, HSGAG binding to ligands 
stabilizes FGFs against degradation, and serves as a storage for ligands 
which also control the rate of ligand diffusion [12]. 
Downstream signaling and its negative regulation. Ligand dependent 
dimerization results in a structural shift in the FGFR receptor to activate 
the intracellular kinase domain that leads to an intermolecular trans-
phosphorylation of the tyrosine kinase domains of the receptor. The 
phosphorylated tyrosine residues serve as docking site for the adaptor 
proteins [13], such as FGFR substrate 2 (FRS2), which are 
phosphorylated by FGFRs, resulting in the activation of multiple signaling 
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pathways. Among all of the adaptor proteins, FRS2 is the primary adaptor 
highly unique to FGFR signaling instead of other growth factor receptors. 
FRS2 binds to the intracellular domain of FGFRs using its 
phosphorylation-binding domain (PTB), and is then phosphorylated by the 
activated FGFRs. The activated FRS2 recruits its own adaptor proteins, 
SOS) and GRB2 to activate the downstream signaling pathway [13]. In 
addition, GRB2 associated binding protein 1 acts downstream of FGFR 
separately from FRS2 to activate an PI3K/AKT-dependent pathway [14]. 
Independent of FRS2 binding, a separate site in the intracellular portion of 
the activated FGFR binds to the SH2 domain of phospholipase Cγ (PLCγ). 
The activation of PLCγ facilitates protein kinase C (PKC) signaling [15,16], 
which partially augments the activation of MAPK pathway (Figure 1.2).  
Following activation of FGFR signaling, signal attenuation and negative 
pathway feedback control could take places. First, FGFRs are internalized 
and then degraded, which is partially mediated by CBL-mediated mono-
ubiquitylation [17]. Second, MAPK phosphatases such as MAPK 
phosphatase 3 and others phosphatases from Sprouty and SEF family are 
activated followed by FGFR activation to reduce the level of downstream 
signaling [18-21]. These proteins modulate the MAPK signal transduction 
cascade at multiple points [22]. 
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Figure 1.2 FGFR signaling network. The signal transduction network 
downstream of fibroblast growth factor (FGF) receptors (FGFRs), along 
with negative regulators. Following ligand binding and receptor 
dimerization, the kinase domains transphosphorylate each other, leading 
to the docking of adaptor proteins and the activation of four key 
downstream pathways: RAS–RAF–MAPK, PI3K–AKT, signal transducer 
and activator of transcription (STAT) and phospholipase Cγ (PLCγ) 
(green). Signaling can be negatively regulated at several levels by 
receptor internalization or the induction of negative regulators, including 
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FGFR-like 1 (FGFRL1), SEF, Sprouty (SPRY), CBL, MAPK phosphatase 
1 (MKP1) and MKP3 (brown). Reprinted from Turner N, Grose R, Nat Rev 
Cancer. 2010 Feb;10(2):116-29 with the permission from Nature 
Publishing Group. 
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Physiological function of FGF-FGFR signaling. FGF-FGFR signaling 
plays a vitally essential role in embryonic development, wound healing, 
and tissue cross-talk.  
Several of the 18 FGFs expressed in human cells are vital for embryonic 
development due to their essential roles in stimulating cell growth and 
migration. Specifically, extensive studies in mouse genetic models and 
human pathologies have indicated a pivotal role of FGFs in embryology 
from gastrulation to organogenesis [13,23,24]. For instance, FGF8 
knockout mice display defects in gastrulation [25], and FGF9 and FGF10 
knockout mice die at birth due to their inabilities to develop functional 
lungs [26,27]. In humans, FGF3 and FGF10 are associated with hereditary 
aplastic syndromes [28,29]; FGF20 is involved in Parkinson’s disease 
[30,31]. In addition, defects of FGFRs mostly cause skeletal and growth 
defects in mouse models [32,33].  
FGF-FGFR signaling also functions in wound healing and tissue repair in 
adults. In the process of wound healing, several FGFs, including FGF1, 2, 
7 and 10, are released from the extracellular matrix to stimulate 
proliferation and migration in both mesenchyme and epithelium to 
accomplish wound closure and re-epithelialization [34,35]. FGF2 also has 
been shown to stimulate neovascularization, which is an essential 
component of the overall wound healing [36]. In parallel, endothelial cells 
express the IIIc isoforms of FGFR2 and FGFR3 in response to FGFs 
11 
 
stimulation [37].In addition, previous studies have shown the involvement 
of FGF16 and FGF18 in angiogenesis in cardiac tissue [38]. 
The cellular process of epithelial-mesenchymal tissue cross-talk plays an 
essential role in both embryonic development and wound healing. The 
interaction between these two tissue types is achieved by tissue specific 
FGFR variants generated by alternative splicing corresponding to FGFs 
produced in the respective tissue microenvironment [39,40]. As a result, 
the IIIb isoform of FGFR2 is predominately expressed in epithelia, 
whereas the IIIc isoform primarily exists in mesenchyme [8]. 
1.1.2. Deregulation of FGF-FGFR signaling in cancer 
There is substantial evidence that supports the presence of aberrant FGF 
signaling in multiple types of malignancies. The underlying mechanisms of 
deregulation are manifold and largely tumor specific, but they can be 
divided into two groups. One group is genomic FGFR alterations including 
activating mutation, FGFR gene amplification and chromosomal 
translocation that result in ligand-independent receptor signaling. In 
contrast, the other group is alterations that drive ligand dependent 
activation including deregulation of autocrine and paracrine signaling and 
germline single nucleotide polymorphisms (Figure 1.3). 
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Figure 1.3 Mechanisms of pathogenic cancer cell FGF signalling. The 
ways in which fibroblast growth factors (FGFs) and FGF receptors 
(FGFRs) can be altered in cancer fall into four main groups. a. Genomic 
alteration of FGFR can occur through three mechanisms, leading to 
ligand-independent signalling. First, activating mutations can result in 
ligand-independent dimerization or constitutive activation of the kinase 
(shown by yellow lightning). Second, chromosomal translocations can also 
lead to ligand-independent signalling. Intragenic translocations generate 
fusion proteins, usually with the amino terminus of a transcription factor 
fused to the carboxy-terminal FGFR kinase domain, resulting in 
dimerization of the fusion protein and constitutive signalling. b. 
Establishment of a paracrine loop. Altered FGFR expression on a cancer 
cell can potentially occur by splicing, which alters FGFR specificity, or by 
amplification of an FGFR gene to express FGFR out of context, which is 
13 
 
activated by FGF (green) expressed by a stromal component. Tumour 
cells can stimulate stromal cells to release FGF ligands and increase the 
release of ligands from the extracellular matrix. c. Establishment of an 
autocrine loop. FGF ligands are produced in an autocrine fashion by a 
cancer cell (brown). The autocrine loop can be established by FGFR 
expression out of context or by the increased expression of FGF ligands.  
d. FGF stromal effects, including angiogenesis. FGF released from 
stromal cells or cancer cells can act on endothelial cells to promote 
angiogenesis. Reprinted from Turner N, Grose R, Nat Rev Cancer. 2010 
Feb;10(2):116-29 with the permission from Nature Publishing Group. 
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Activating mutations. A profile of kinase gene mutation status from 210 
different human cancers highlights the importance of FGFR mutation in 
tumor pathogenesis [41]. Substantial evidence suggests that FGFR 
mutations are most frequently associated with the development of 
urothelial cancer [42], although this type of mutation is identified in other 
types of cancers including multiple myeloma, prostate cancer and cervical 
cancer [43,44]. In addition, ~60% of urothelial cancers overall have 
somatic mutations in the FGFR3 coding region, and mutations are 
predominantly associated with non-muscle invasive urothelial cancers, 
whereas only 10-15% of muscle invasive urothelial cancers carry FGFR3 
mutations [45]. The most common FGFR3 mutation (>50%) occurs in the 
extracellular domain named S249C, where this point mutation leads to 
constitutive receptor dimerization and activation independently of ligands 
[46,47]. Mutations also occur in the transmembrane domain such as 
S371C, and in the kinase domain such as K652E, but less frequently. 
Both mutations lead to constitutive activation of the receptors [48]. 
Interestingly, recent studies indicated that FGFR3 mutations more 
commonly co-exist with PIK3CA mutations in urothelial cancer, whereas 
FGFR3 mutations do not co-exist with HRAS mutation [49,50]. In addition, 
FGFR2 mutations do not coincide with KRAS mutations in endometrial 
cancer [51]. 
Gene amplifications. In general, amplification of FGFR1 and FGFR2 are 
identified more frequently than FGFR3 amplification [52], and FGFR3 
15 
 
amplification occurs much less frequently than activating mutation of 
FGFR3. FGFR1 amplification has been mostly studies in breast cancer 
which occurs at ~10% of all breast cancer cases, largely in estrogen 
receptor positive type [53,54]. In addition, amplification of FGFR1 was 
observed in ovarian cancer, lung cancer and bladder cancer but to a 
lesser extent [55-57]. However, it is still debatable whether higher level of 
FGFR1 leading to tumorigenesis by aberrantly responding to paracrine 
FGF ligands or by ligand independent activation of the signaling pathway. 
In general, FGFR2 amplification was reported in ~10% of gastric cancers 
[58,59]. Strong evidence suggests that FGFR2 amplification in gastric 
cancer cells results in ligand independent signaling, although paracrine 
secretion of FGF7 may partially promote cellular proliferation in vivo [60]. 
Chromosomal translocations. A good example of FGFR chromosomal 
translocation come from the study of multiple myeloma, where 15% of 
cancers harbor a t(4:14) translocation that directly connects FGFR3 at 
4p16.3 to the immunoglobulin heavy chain IGH locus at 14q32 [61]. The 
intergenic translocation with the breakpoints at ~70kb upstream of FGFR3, 
renders the FGFR3 gene to be controlled by highly active IGH promoter. 
Ultimately, the consequence of the translocation is to cause high level 
overexpression of FGFR3, which leads to aberrant ligand dependent or 
independent signaling [62]. It is also important to note FGFR3 mutations 
exist in a fraction (~5% cases) of the t(4:14) multiple myeloma, which 
would possibly further reinforce the FGFR3 signaling [63]. The importance 
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of this t(4:14) translocation in multiple myeloma has been modeled using 
transgenic mice [61], and is associated with poor prognosis. Studies also 
demonstrated the t(4:14) myeloma cells are highly sensitive to FGFR3 
inhibition [64,65]. In addition, several FGFR intragenic translocations have 
been discovered, which typically results in a fusion protein comprised of 
the N terminus of a transcription factor fused onto an FGFR kinase 
domain which leads to constitutive FGFR dimerization and activation [66-
68]. 
In urothelial cancer, a recent study identified a new FGFR3-TACC3 
translocation, where FGFR3 at 4p16.3 is re-arranged to form a t(4:7) 
translocation that results in a FGFR3-BAI1-associated protein 2-like 1 
(BAIAP2L1) fusion at RT112, RT4 and SW780 [69]. The fusion receptor 
causes high levels of ligand independent activation of FGFR3. Several 
other studies have demonstrated that these cells exhibited a high level of 
dependency on FGFR3 signaling and were extremely sensitive to FGFR 
inhibition [47,49,70], which suggested that this translocation might be the 
determinant of FGFR dependency in RT112, RT4 and SW780. It is still 
unclear which mechanism causes the activation of FGFR signaling by the 
FGFR3-TACC3 fusion protein. However, William et al [69] suggested that 
the loss of the C-terminus of the FGFR3 in this translocation was not 
sufficient to cause the activation of FGFR signaling, which implicates that 
presence of fusion partners in this FGFR3-TACC3 translocation. 
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1.2. Epidermal growth factor receptor in cancer 
1.2.1. The EGFR signaling system 
The epidermal growth factor receptor (EGFR) is a transmembrane 
tyrosine kinase receptor of the ErbB family [71,72]. The ErbB family is 
consist of four related receptors: EGFR (Erb1/HER1), ErbB2 (HER2/neu), 
ErbB3 (HER3), and ErbB4 (HER4) [73,74]. EGFR activation engages 
three major downstream signaling pathways including MAPK/Erk pathway, 
PI3K/AKT and PKC pathway. These three pathways are cross-connected 
at multiple points that lead to signal interaction, integration and ultimately 
pathway cascade. As a result, the activation of EGFR in a particular cell 
results in a variety of biological consequences [74]. Specifically, receptor 
activation recruits and phosphorylates multiple intracellular substrates, 
which leads to pathway cascade that engage cellular functions including 
cell proliferation, growth and survival, cell migration and invasion, 
angiogenesis and tumor metastasis. 
EGFR signaling. Similar to FGFR signaling, the EGFR signal cascade is 
comprised of three phases that are ligand binding and sub-sequential 
receptor dimerization and activation, phosphorylation of cytoplasmic 
substrate to initiate intracellular signaling cascade, and finally various 
cellular responses driven by diverse gene transcription activities [73]. 
EGFR is comprised of an extracellular region (ectodomain), a 
transmembrane domain, and an intracellular kinase domain with a 
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regulatory carboxyl terminal segment [75]. The ectodomain is composed 
of two types of sub-domains, namely the L domain and a cysteine-rich 
(CR) domain [73], where only the L type of domain is used for ligand 
binding. A variety of ErbB family ligands bind to EGFR and drive homo- or 
hetero-dimerization with the other three ErbB receptors [76-78]. However, 
EGF and transforming growth factor-α (TGFα) are believed to be the most 
important ligands for EGFR [79]. Following ligand binding, EGFR 
extracellular domains undergo substantial structure re-configuration that 
leads to homo- and hetero-dimerization of receptors [77], which activate 
the intrinsic EGFR tyrosine kinase domain and sub-sequential 
autophosphorylation of the receptor intracellular kinase domain. Followed 
by the activation of EGFR tyrosine kinase, multiple intracellular substrates 
including SOS and GRB2 are recruited to specific phosphotyrosine sites 
on the receptor [80]. There are 3 major downstream signaling pathways 
induced by EGFR activation. One of them is Ras/Raf/MAPK pathway. The 
activation of Ras by adaptor molecules Grb2/SOS initiates the activation 
of mitogen-activated protein kinases (MAPKs) and ERK1/2 through 
multiple steps of signal cascade, which in turn regulate transcription 
factors linked to cell proliferation and survival [81]. The second signaling 
route in EGFR activation is the PI3K/AKT pathway [82,83], which 
transduces a signal cascade to trigger cellular responses ranging from cell 
proliferation and survival to migration and invasion. The third downstream 
signaling is through protein kinase C and Stat. The activation of this route 
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initiates distinct transcriptional events that regulate a variety of cellular 
responses including cell survival, invasion and DNA repair [73]. 
1.2.2. Deregulation of EGFR in cancer 
Similar to FGFR deregulation in cancer, deregulation of tightly controlled 
EGFR signaling drives the development of malignancy (oncogene 
addiction) in multiple types of cancer. Among them, non-small cell lung 
carcinoma (NSCLC) is the mostly investigated due to its higher 
occurrence of EGFR deregulation and relative favorable response to 
EGFR targeted therapy compared to other types of cancer.  
Several mechanisms of EGFR alteration, including EGFR gene 
amplification and activating mutation, overexpression of receptor and 
ligands, and/or loss of negative feedback regulation[84], could lead to the 
abnormal receptor activation, which ultimately drives the tumor 
development and progression. Below we will discuss the two most 
extensively studied EGFR alterations: EGFR gene amplification and 
activating mutation. 
EGFR gene amplification. One of the most investigated EGFR 
alternations is activation of EGFR signaling through increased gene copy 
number through amplification. EGFR is frequently overexpressed in many 
human tumors including breast and lung cancer, head and neck cancer, 
urothelial cancer, colorectal cancer, ovarian cancer, prostate cancer, and 
glioblastoma [85]. The increased expression can exceed a threshold, 
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which results in ligand independent constitutive activation of its tyrosine 
kinase and signal cascade that drives EGFR oncogene addiction [74,86]. 
Elevated EGFR expression is a strong prognostic marker in head and 
neck cancer, ovarian cancer and bladder cancer [87]. Specifically, a great 
number of studies indicated that the increased EGFR expression highly 
correlated with poor clinical outcomes in multiple types of cancer, 
including breast, lung, head and neck, and urothelial cancers [88,89]. 
Furthermore, elevated EGFR gene copy number is associated with 
increased clinical response to EGFR TKI erlotinib and mAbs cetuximab in 
NSCLC [90]. 
Activating mutation. EGFR activating mutations were first reported in 
NSCLC through retrospective studies of EGFR mutation status in early 
clinical trials of gefitinib or erlotinib [91]. It was then discovered that EGFR 
activating mutations are strongly predictive of benefit from EGFR targeted 
therapy [91] mainly because the gain-of-function mutation drives 
continued oncogenic signaling (oncogene addiction). Up to date, there are 
two most common mutation types that account for >90% of EGFR 
mutations revealed in NSCLC. Mutations in exon 19 that account for 45-
50% of EGFR mutation incidence result in small in-frame deletions [92]. 
The second most common mutation locating in exon 21 (activation loop of 
EGFR) is a point mutation L858R that comprise about 45% of EGFR 
mutation [92]. Overall, the activating mutations cause ligand independent 
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activation of EGFR signaling and simultaneously result in EGFR oncogene 
addiction. 
Additionally, EGFR mutations can be accompanied by gene amplification. 
For example, EGFRvIII, a deletion variant that lacks exon 2-7 
(extracellular domain), forming a constitutively active receptor was found 
predominantly in malignant gliomas (20%-30%), where 50%-60% of 
patients bearing the mutation also showed amplification of wild type EGFR 
[93]. Follow up studies revealed that EGFRvIII was also expressed in 
head and neck cancer, lung cancer and breast cancer, although the 
occurrence rate was not as high as it is in malignant gliomas [94]. 
 
1.3. Role of FGFR and EGFR signaling in the development of 
bladder Cancer 
1.3.1. Bladder cancer stratification and management 
Bladder cancer occurs with a very high incidence worldwide. Each year, 
~400,000 new cases are diagnosed and ~ 150,000 disease-related deaths 
occur [95]. In United States, BC was ranked as the fourth most common 
malignancy and eighth most common cancer-related death in men in 2012 
[96].  The most frequent histologic type of BCs is urothelial carcinoma 
(UC) (~90%), whereas squamous cell carcinoma and adenocarcinoma 
combined accounts for <10% of BCs [97]. BCs are diagnosed using the 
TNM classification system along with tumor grade, which helps surgical 
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and medical oncologist to determine the treatment regimens and to predict 
the prognosis. The TNM classification system describes the depth of 
tumor penetrating into the bladder tissue (T), the status of regional lymph 
node (N) and the presence or absence of distant metastases (M). 
Bladder cancer can be separated into two major phenotypic variants: 
superficial non-muscle-invasive UCs and muscle invasive UCs [98]. Up to 
80% of the BCs are superficial non-muscle-invasive tumors at the time of 
diagnosis [97]. These tumors arise from hyperplastic urothelium and tend 
to localize within the bladder lining and connective tissues, therefore only 
a small portion (~20%) will eventually progress to become invasive 
tumors. The non-muscle-invasive BCs are normally managed by 
cytoscopic resection with or without intravesical instillation of 
immunotherapy agents including bacillus Calmetee-Guerin (BCG) [99]. 
However, up to ~70% of these tumors recur as non-muscle-invasive 
disease, which results in the need for long-term surveillance and frequent 
tumor resection and disease management, therefore making BC one of 
the most expensive malignancies to manage [99]. On the other side, 
~20% of BCs are muscle-invasive tumors at the time of diagnosis [97]. 
These tumors arise from severe dysplasia or carcinoma in situ (CIS) and 
tend to invade into bladder muscle layer and finally metastasize to 
regional lymph nodes and distant organs. Therefore, muscle-invasive BCs 
are highly lethal. The standard care for muscle invasive BCs is radical 
cystectomy, with or without adjuvant or neoadjuvant chemotherapy [99]. 
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Regardless of recent advance in radical cystectomy, chemo-radiation 
therapy, chemotherapy and targeted therapy, 50% of the muscle-invasive 
BC patients die after 5 within of diagnosis [99]. Therefore, it is very 
important to identify the molecular mechanisms underlying the metastatic 
profile of muscle-invasive BC and progressive profile of superficial BC into 
muscle invasive phenotype. 
1.3.2. Role of FGFR and EGFR signaling in bladder caner 
Multiple mechanisms of FGFR activation in bladder cancer have been 
identified in recent studies. For example, ~70% of low grade non-muscle-
invasive BCs carry FGFR3 mutations which drive ligand independent 
activation of FGFR3 [100]. Furthermore, several studies have provided 
direct evident to support the cause-effect link between the present of 
FGFR3 activating mutations and bladder cancer tumorgenesis [101,102]. 
Moreover, overexpression of FGFR3 and FGFR1 accounts for ~25% and 
15% of this disease respectively [97,103]. Experimental studies have 
identified FGFR1 activation as the underlying mechanism that drives cell 
proliferation and invasion [103,104]. Overall, FGFR signaling is showed to 
mediate cell proliferation, cell migration and invasion and tumor growth 
and metastasis in bladder cancer [70,104,105]. Moreover, FGFR inhibitors 
showed substantial inhibitory effects against proliferation, invasion and 
tumor metastasis in preclinical models both in vivo and in vitro 
[70,103,104]. In summary, FGFR signaling is activated in bladder cancer 
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to drive tumor development and progression, which provides a rationale 
for FGFR targeted therapy in bladder cancer patients. 
Similarly, EGFR signaling has long been implicated in bladder cancer 
though the molecular mechanism by which EGFR regulates bladder 
cancer biology are still not very clearly defined. For example, EGFR 
overexpression in bladder cancer is reported by several studies [106,107] 
and the overexpression of its ligands in bladder cancer is also revealed by 
other studies [108,109] . Overall, EGFR signaling is found to regulate cell 
proliferation and tumor growth, cell migration and invasion, and 
angiogenesis in bladder cancer [110]. Additionally, the overexpression of 
EGFR highly correlates with not only tumor grade and stage [111], but 
also patient survival [112]. Furthermore, previous work showed that 
transgenic overexpression of EGFR in bladder cancer cells promotes 
tumor development and progression in xenograft [113], which directly 
supported the role of EGFR in driving tumor biology of bladder cancer. 
Moreover, clinically relevant EGFR antagonists and inhibitors showed 
significant anti-proliferative and anti-angiogenic effects in preclinical 
research [114,115]. In summary, all of the evidence provides direct 
rationale to clinically target EGFR in bladder cancer patients. 
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1.4. FGFR and EGFR targeted therapy 
As discussed above, manifold experimental evidence suggested the role 
of deregulated FGFR and EGFR in certain cancers including bladder 
cancer, lung cancer, head and neck cancer, colon cancer and multiple 
myeloma. Moreover, preclinical studies found significant anti-tumor 
activities of FGFR and EGFR antagonists both in vitro and in vivo. 
Therefore, investigating clinical utilization of FGFR and EGFR targeted 
therapy has become the frontier of translational and clinical research, and 
there is high level of enthusiasm to develop promising novel agents for 
FGFR and EGFR targeted therapy given the urgent needs to seek better 
treatment paradigms to improve patient outcome in clinic.  
Although several approaches have been tested to target FGFR and 
EGFR, the two most extensively studied and advanced approaches are 
monoclonal antibodies [116] (mAbs) directly against the receptors 
extracellular region and low-molecular-weight tyrosine kinase inhibitors 
(TKIs) [117] that interfere with intracellular tyrosine kinase domain (Figure 
1.4). The antibodies bind to the extracellular region of the receptors and 
compete with ligands, whereas the TKIs compete intracellularly with ATP 
for binding sites at receptor’s tyrosine kinase domain. However, at the 
downstream level of signaling pathways, antibodies and TKIs have similar 
effects because both of the approaches lead to an effective blockade of 
the primary downstream signal transduction including the MAPK pathway 
[118], the PI3K/Akt pathway [119], and the PKC/Stat pathway [120]. In 
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contrast, there may be two differences between mAbs approach and TKIs 
approach. Firstly, mAbs instead of TKIs are able to form a complex 
containing receptor that leads to receptor internalization [95], which in turn 
cause signal attenuation. Secondly, mAbs but not TKIs also have the 
capability to induce antibody-dependent cellular cytotoxicity (ADCC) [96]. 
Below, we will separately discussed FGFR and EGFR targeted therapy 
and their clinical development. 
1.4.1. FGFR targeted therapy 
Currently, FGFR targeted therapy is still at an early stage of clinical 
development where most of the development efforts are focus on anti-
FGFR TKIs. Two FGFR specific TKIs are being evaluated in clinical trials 
despite the fact that multiple other FGFR antagonists have showed anti-
tumor activity in preclinical research [121,122]. One of them is BGJ-398 
(Figure 1.5 for structure, Table 1.2 for in vitro IC50) that is developed by 
Novartis and is evaluated in advanced solid tumor with FGFR1 or FGFR2 
amplification or FGFR3 mutation in phase I clinical trial on does escalation 
studies (NCT01004224). Another one is AZD4547 (Figure 1.5 for 
structure, Table 1.2 for in vitro IC50), developed by AstraZeneca that just 
finished its phase I clinical trial with advanced solid tumors 
(NCT01213160). The drug is currently tested in phase II clinical trials in 
solid tumors (NCT01795768) as single drug or in combination with 
hormonal therapy for breast cancer patients (NCT01202591) or in 
combination with 
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Figure 1.4 Schematic diagram depicts two approach for targeted therapy. 
Left panel, FGFR-specific monoclonal antibodies bind the extracellular 
domain of the receptor and inhibit FGFR signaling, causing changes in 
tumor cell proliferation and survival. 
Right panel, treatment of tumor cells with TKIs such as PD173074 or 
TKI258 blocks ligand-induced FGFR activity and constitutive FGFR 
signaling from mutated or amplified receptors. FRS2 Tyr phosphorylation 
decreases, causing an uncoupling of Grb2 from the adaptor protein and a 
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decrease in ERK and AKT activity. Adapted from Nancy E. Hynes et al., 
2010, Cancer Res; 70(13); 5199–202 with the permission from American 
Association for Cancer Research. 
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chemotherapy for advanced gastric cancer or NSCLC patients 
(NCT01824901, NCT01457846). Regarding the mAb approach, a specific 
inhibitory monoclonal antibody targeting FGFR3 was development by 
Genentech, R3Mab [64] and is currently tested in preclinical models 
[64,123]. The preclinical study results provided direct in vitro and in vivo 
proof to support the translation of into clinical trials in patients with either 
bladder cancer or hematologic cancer. Overall, the various biological 
function of FGFR makes it very attractive therapeutic target, and future 
clinical development efforts are needed for proof-of-concept and 
developing successful clinical strategies to target FGFR. 
1.4.2. EGFR targeted therapy 
Compared to FGFR targeted therapy, EGFR targeted therapy has been in 
development for years, and there are several successful stories. 
Cetuximab [88], a chimaeric anti-EGFR mABs, was approved by the FDA 
for treating patients with advanced colon cancer refractory to irinotecan 
(CPT-11) in 2004. Other examples are gefitinib (Iressa, ZD1839) (Figure 
1.5 for structure, Table 1.2 for in vitro profile of IC50) and erlotinib, anti-
EGFR TKIs. Gefitinib showed increased patient response rate in non-
small cell lung cancer (NSCLC) from multiple phase II clinical trials 
[124,125], which led to accelerated FDA approval for treatment of 
advanced NSCLC refractory to  
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Figure 1.5 Structure of BGJ-398 [126], AZD4547 [127] and Gefitinib 
[128]. 
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A. in vitro profile of BGJ-398 and AZD4547 
Kinase Enzyme IC50 (μM) Cellular IC50 (μM) 
 BGJ-398 AZD4547 BGJ-398 AZD4547 
FGFR1 0.0009 0.0002 0.0029 0.012 
FGFR2 0.0014 0.0025 0.0020 0.002 
FGFR3 0.0010 0.0018 0.0020 0.040 
FGFR4 0.060 0.165 N/A 0.142 
VEGFR2 0.18 N/A 1.449 N/A 
IGFR >10 0.581 N/A 0.828 
EGFR >10 >100 N/A N/A 
erbB2 >10 >100 N/A N/A 
erbB3 >10 >100 N/A N/A 
erbB4 >10 >100 N/A N/A 
AKT >10 >100 N/A N/A 
PI3K >10 >100 N/A N/A 
*reference: [126,127] 
B. in vitro profile of Gefitinib 
Kinase Enzyme IC50 (μM) 
EGFR 0.027 
erbB2 6.8 
Raf >10 
MEK-1 >10 
ERK-2 >10 
*reference: [128] 
Table 1.2 selectivity of BGJ-398, AZD4545 and Gefitinib 
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chemotherapy in 2003. Additionally, FDA approved erlotinib for treatment 
of metastatic NSCLC patients with EGFR exon 19 deletions or exon 21 
substitution mutation in 2013 [129]. However, the follow up studies 
revealed that anti-EGFR agents, either mAbs or TKIs failed to improve 
survival benefit (overall survival) although tumor regression was 
achienved in multiple large clinical trials in NSCLC [130]. These 
observations reduced enthusiasm for continuous development of EGFR 
targeted therapy, and led to limited FDA approval for EGFR targeted 
therapy and restricted use of gefitinib in NSCLC patients. Therefore, it is 
of pivotal importance to investigate and discover biomarkers that can lead 
the selection of patients who are predicted to benefit from EGFR targeted 
therapy. 
In bladder cancer, there is continued interest in EGFR targeted therapy. 
Specifically, multiple clinical trials that evaluate EGFR targeted therapy 
agents in conjunction with conventional chemotherapy underway. For 
example, erlotinib is being evaluated in muscle invasive bladder cancer 
patients both before and after surgery (NCT00380029). Overall, EGFR still 
remains as an attractive target in bladder cancer and future development 
efforts should focus on investigating clinical applicable biomarkers to 
identify the appropriate subset of patients who can benefit from EGFR 
target therapy strategy. 
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1.5. Escape mechanism of EGFR and FGFR targeted therapy 
Various drugs targeting EGFR, through either mAbs or TKIs, have proven 
effective in subsets of patients in several types of cancer. Good examples 
are Cetuximab, a chimeric monoclonal antibody that is specific for the 
extracellular domain of the receptor, and gefitinib and erlotinib, TKIs 
competing with ATP for intracellular binding domain of the receptor, which 
have been approved for the treatment of several cancer types [72,84]. 
However, the majority of patients do not respond to EGFR targeted 
therapy and a high rate of acquired resistance to these therapeutic drugs 
is observed in patients that do respond [131], suggesting both intrinsic and 
acquired mechanisms of resistance. Recently, a number of studies 
indicated a secondary mutation of egfr, and activities of other tyrosine 
kinase receptor including cMET, IGF-1R and FGFRs as mechanisms for 
resistance. Thus, it is necessary to further understand the resistance 
mechanisms that help the development of novel strategies to overcome 
such resistance. 
In contrast, FGFR targeted therapy is still at its early stage of 
development. Due to the incidence of FGFRs as oncogenic determinants 
in certain types of cancer including bladder cancer, there is a growing 
interest in developing selective FGFRs tyrosine kinase inhibitors. A good 
example is AZD4547, a pan FGFR1-3 inhibitor, which has recently 
entered clinical trials [127]. However, the success of FGFR targeted 
therapy will require knowledge of mechanisms of both intrinsic and 
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acquired resistance. So far, two individual studies identified the EGFR 
activation [132] and a gatekeeper mutation in FGFR3 [133] as two 
separate escape mechanisms of FGFRs target therapy and I will present 
details below.  
1.5.1. Escape mechanisms of FGFR targeted therapy 
Secondary V555M gatekeeper mutation of fgfr. Recently, Chell et al 
[133] generated a derivative of the KMS-11 myeloma cell line 
(FGFR3Y373C, originally sensitive to FGFR inhibition) named KMS-11R by 
long-term exposure to an FGFR inhibitor (AZ8010), and showed that the 
KMS-11R acquired resistance to AZ8010. The KMS-11R cell line was also 
cross-resistant to multiple FGFR TKIs (AZD4547 and PD173074). 
Sequencing of FGFR3 in the KMS-11R cells demonstrated the presence 
of a heterozygous mutation at the gatekeeper residue, encoding 
FGFR3V555M, which restricts the access of FGFR TKIs to the ATP binding 
pocket of the FGFR3. That structural change of the FGFR3 intracellular 
kinase domain enables this particular cell line to become resistant to 
FGFR antagonist. The resistant KMS-11R cells exhibits a constitutive 
activation of FGFR signaling regardless of the presence of FGFR TKIs. 
Re-activation of EGFR signaling. A recent study by Turner’s group [132] 
demonstrated that intrinsic or acquired activation of the EGFR contributes 
to the resistance of FGFR TKIs in FGFR3 activated cells. Their study 
showed that EGFR signaling was up-regulated following FGFR inhibition 
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though impaired EGFR receptor trafficking and the release from negative 
feedback in FGFR3 dependent cells, and combining the EGFR TKI with 
the FGFR TKI produced synergistic growth inhibition compared to the 
effects of inhibiting either receptor alone. These data suggested re-
activation of EGFR signaling compensates for the loss of FGFR signaling 
that allows the cells to escape from FGFR inhibition. They also 
investigated mechanisms for the intrinsic resistance to FGFR inhibition, 
and suggested that dominant EGFR signaling in cell lines otherwise 
bearing activating FGFR3 mutation which represses the expression of 
mutant FGFR3 expression and leads to the intrinsic resistance to FGFR 
TKIs. 
1.5.2. Resistance mechanisms of EGFR targeted therapy. 
Secondary T790M mutation of egfr. The presence of a secondary 
mutation of the egfr, which leads to a change from threonine (T) to 
methionine (M) at position 790, was first reported in 2005 [134,135]. The 
occurrence of the point mutation in tumors that were originally sensitive to 
EGFR TKIs led to development of resistance to EGFR TKIs [135]. 
Structural studies of the intracellular kinase domain of EGFR revealed that 
T790M was located in the ATP binding pocket to which EGFR TKIs binds 
[136]. It was also demonstrated by structure analysis that the T790M point 
mutation results in a higher affinity to ATP and a relative lower affinity to 
EGFR TKIs [136]. The T790M mutation presents in approximately 50% of 
lung adenocarcinoma tissue as reported in the studies using clinical 
36 
 
specimens with acquired resistance to EGFR TKIs [137]. In contrast, 
tumor cells harboring the T790M mutation only constituted a minority of 
the cells before EGFR TKIs treatment. Therefore, the T790M point 
mutation was identified as a marker for acquired resistance to EGFR TKIs. 
In addition, previous studies indicated that the T790M mutation of egfr 
caused increased kinase activity, while exhibiting higher level of tyrosine 
phosphorylation as compared to wild-type EGFR, and showing a growth 
advantage over wide-type cells [138,139]. 
MET amplification and HGF overexpression. The MET amplification 
was reported in HG827GR, a human lung adenocarcinoma cell line with 
acquired resistance to EGFR TKIs, in 2007 [140]. Several studies showed 
MET amplification caused the autophosphorylation of MET itself, 
heterodimerization with HER3, and activation of the PI3K/Akt pathway in 
EGFR TKI resistant cells [140-142]. Thus, the constitutive activation of 
PI3K/Akt pathway independent of EGFR activation leads to the failure of 
EGFR TKIs, which results in the acquired resistance to EGFR TKIs. The 
analysis of clinical lung adenocarcinoma specimens revealed the 
incidence of MET amplification is approximately 20% in patients with 
acquired resistance [140]. It was also demonstrated that the MET 
amplification was independent of T790M point mutation in lung tumors 
[141]. In parallel, the overexpression of HGF, the main ligand for the MET 
tyrosine kinase receptor, was identified as another mechanism of 
resistance to EGFR TKIs [143]. Unlike MET amplification, overexpression 
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of HGF stimulates the PI3K/Akt pathway through MET phosphorylation 
that is independent of HER3 activation. Furthermore, it was reported that 
HGF promotes MET amplification and coexists with T790M mutation in 
patients with acquired EGFR TKIs resistance [144]. Together, these 
studies suggested that MET/HGF activation is one mechanism of EGFR 
resistance. 
De-repression of FGFRs. Recently, Ware et al [145] reported that 
increased levels of FGFRs mRNA was observed in non-small cell lung 
cancer (NSCLC) cells treated with EGFR TKIs, suggesting an activated 
FGFR signaling after inhibition of EGFR pathway. They further confirmed 
that FGFR induction could result in FGFR signaling through ERK pathway. 
The study also demonstrated that either exposure to exogenous FGF2/7 
or co-culture of NSCLC cells with human fibroblasts could rescue growth 
inhibition induced by EGFR TKIs in NSCLC cells via an FGFR dependent 
manner. In a separate study, Thomson et al [146] revealed that NSCLC 
cells with a mesenchymal phenotype exhibited remarkable reduction in 
sensitivity to EGFR specific monoclonal antibody, and also a decreased 
expression and phosphorylation of EGFR. However, these same cells 
showed aberrantly escalated FGFR expression and autocrine signaling 
that activates the MAPK and PI3K/Akt pathway. Their data suggested that 
activated FGFR signaling played a redundant pathway in NSCLC cells 
leading to the intrinsic resistant to EGFR monoclonal antibody. Together, 
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these results indicated activation of FGFRs tyrosine kinase signaling as 
one mechanism of resistance to EGFR inhibition. 
1.6. Rationale of the study 
It is evident that bladder cancer is one of the leading cancer types with 
respect to both occurrence and lethality in the US [96]. Therefore, it is 
critical to understand the biology of bladder cancer progression and 
metastasis in order to improve the management of the disease with the 
ultimate purpose to discover a “cure” for bladder cancer. Given the 
potential FGFRs and EGFR addiction that bladder cancer possesses, 
which was highlighted by recent publications [103,104,114,115], a great 
amount of research focuses on developing strategies to target FGFR and 
EGFR in bladder cancer. However, there exist remarkably heterogeneous 
responses to both EGFR and FGFR targeted therapy revealed by recent 
studies [70,115]. Therefore, it is crucial to understand the molecular 
mechanisms that drive such heterogeneity and to identify clinical 
biomarkers associated with the subsets patients who can maximally 
benefit from FGFR and/or EGFR target therapy. Hence, in this 
dissertation, I seek to better understand the role of FGFRs in driving 
distinct cell functions proliferation versus invasion, and to dissect the 
mechanisms that regulate discretely non-overlapping and mutually 
exclusive FGFR and EGFR dependency.  
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CHAPTER 2. MATERIALS AND METHODS 
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2.1. Chemicals and Reagents 
BGJ-398, a novel and selective tyrosine kinase inhibitor (TKI) of FGFR1, 2 
and 3, was generously provided by Novartis. Astra Zeneca generously 
provided AZD4547, a novel and selective tyrosine kinase inhibitor (TKI) of 
FGFR1, 2, and 3 (citation), as well as the EGFR TKI gefitinib (ZD1839, 
Iressa®, Astra Zeneca Inc.). For in vitro studies, all three TKIs were 
reconstituted in DMSO at a stock concentration of 10 mmol/L, stored at -
20°C and diluted in medium just prior to use so that the concentration of 
DMSO never exceeded 0.1%. For in vivo studies, TKIs was dissolved in 
1% polyoxyethylenesorbitan monooleate (Tween-80) and 99% deionized 
water to the desired concentration (12.5 mg/ml).  
The antidiabetic drug rosiglitazone, a potent peroxisome proliferator 
activated receptor γ (PPARγ) agonist, was purchased from Cayman 
Chemical as were the PPARα activator Wy14643, the PPARγ antagonist 
GW9662, and the PPARβ antagonist Sulindac. The PPARβ agonist L-
165,041 was purchased from Sigma-Aldrich. The PPARα antagonist 
GW6471 was purchased from Tocris Bioscience. PPAR agonists and 
antagonists were stored as stock solutions (100mmol/L in DMSO) at -
20°C and diluted to the desired concentrations just before use.  
Monoclonal antibodies for FGFR1, FGFR3 and bFGF were purchased 
from Cell Signaling. Monoclonal antibodies specific for CHOP, FABP4, 
Ki67 and Phospho-FRS2-α (Tyr436) (rabbit) were purchased from Cell 
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Signaling; antibodies against ERRFI1 and β-Actin (mouse) were from 
Sigma. Horseradish peroxidase-conjugated secondary antibodies were 
purchased from Bio-Rad (anti-rabbit) and Promega (anti-mouse). 
Small interfering RNA (siRNA) Smartpools for FGFR1, FGFR3, CHOP, 
PPARα, β, and γ as well as nonspecific control were purchased from 
Dharmacon. Small hairpin RNAs (shRNA) used for stable FGFR1 
(V3LHS_634640), bFGF (V3LHS_263179), CHOP (V3LHS_646287) and 
FABP4 (V3LHS_407556; V3LHS_407559; V3LHS_353665) knockdown 
as well as Precision LentiORFs derived from cDNA coding sequences for 
CHOP (PLOHS_100066517) and FGFR3 (PLOHS_100066410) 
overexpression were obtained from Open Biosystems. 
2.2. Tumor cell lines and culture conditions 
Cell lines were obtained from the University of Texas MD Anderson 
Cancer Center Bladder SPORE Tissue Bank, and their identities were 
confirmed by DNA fingerprinting using the AmpFlSTR® Identifiler® 
Amplification (Applied Biosystems) or AmpFlSTR® Profiler® PCR 
Amplification (Applied Biosystems) protocols. All cell lines were 
maintained as monolayers in modified Eagle’s MEM supplemented with 
10% fetal bovine serum, 1% vitamin solution (Mediatech), and 0.5% each 
of sodium pyruvate, L-glutamine (Life Technologies), 
penicillin/streptomycin solution, and nonessential amino acids 
(BioWhittaker) at 37°C in a 5% CO2 incubator. 
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2.3. MTT assays 
Cells (5×103) were plated in 96-well plates and allowed to adhere for 24 
hours before they were incubated with or without increasing 
concentrations of BGJ-398 for 48 h or 5 days. MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were used 
to measure relative cell numbers based on conversion of MTT to 
formazan in viable cells. MTT dissolved in PBS (50μg/ml) was added to 
each well and plates were incubated for 2 hours. The medium was then 
removed and 100μl DMSO was added to each well to lyse cells and 
solubilize the formazan. A standard micro-plate reader (PowerWave 340, 
BioTek) was used to determine the absorbance (600 nm). Each 
experimental data point represents average values obtained from six 
replicates and each experiment was performed at least twice. 
2.4. 3H-thymidine assay 
BC cells were plated in 96-well plates supplemented with 10% FBS MEM 
at a density of 5× 10³ cells per well. After 24 hours, the cells were exposed 
to drugs at the indicated concentrations for 48 hours. The medium was 
removed and replaced with fresh MEM containing 1% FBS and 10 μCi/mL 
[Methyl-³H]thymidine (MP Biomedicals) for 2 hours. The media was 
subsequently removed. 100μl of 0.1mol/L KOH were then added to each 
well. The cell lysates were harvested onto fiberglass filter membranes and 
the amount of radioactivity quantified in a scintillation counter (1450 
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MICROBETA Trilux liquid scintillation and luminescence counter; 
PerkinElmer life sciences). Each experimental data point represents 
average values obtained from six replicates and each experiment was 
performed at least twice. 
2.5. Cell cycle analyses 
Cells were plated in 6-well plates and maintained in 10% FBS MEM for 24 
hours. Cells were then exposed to various concentrations of BGJ-398 for 
48 hours or transfected with either FGFR1 or FGFR3 siRNA for 24 hours 
(reaching ~75% to 85% confluence) before they were harvested by 
trypsinization and pelleted by centrifugation. The pellets were then 
resuspended in PI-FACS buffer (50 μg/mL propidium iodide, 0.1% Triton 
X-100, and 0.1% sodium citrate dissolved in PBS). Propidium iodide 
fluorescence was measured by fluorescence-activated cell sorting (FL-3 
channel, Becton Dickinson) using the instrument’s cycle analysis software. 
2.6. Anchorage independent growth assay 
Human BC cell lines UM-UC3 and UM-UC13 wild type or non-targeted or 
bFGF/FGFR1 silenced cells were plated at 1×104 cells per well in 6-well-
plates supplemented with 10% FBS MEM containing 0.6% agar. Cells 
were allowed to grow for 2 weeks. Images were acquired using an 
Olympus IX inverted-phase contrast microscope. The total numbers of 
colonies per random view (100×) and the average diameter of colonies 
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per random view (100×) were determined using a SliderBook image 
analyzer. 
2.7. FGFR3 mutation analyses 
DNA was isolated from BC cell lines using a genomic DNA extraction kit 
(Qiagen). PCR was performed to amplify exons 7 and 10 using AmpliTaq 
Gold DNA polymerase (Applied Biosystems) and the primers 5’-
CGGCAGTGGCGGTGGTGGTG-3’(sense) and 5’-
AGCACCGCCGTCTGGTTGGC-3’ (antisense) for exon 7 and 5’-
CCTCAACGCCCATGTCTTT-3’ (sense) and 5’-
AGGCAGCTCAGAACCTGGTA-3’ (antisense) for exon 10 (Sigma 
Genosys). The following cycling variables were used: 95o C for 10 min, 35 
cycles of 95o C for 30 s, then 65o C (exon 7) or 58o C (exon 10) for 30 s, 
and 72o C for 30 s, followed by a final incubation at 72o C for 10 min. 
Unincorporated primers and deoxynucleotides were removed using 
shrimp alkaline phosphatase and exonuclease I (U.S. Biochemical). 
Products were analyzed by Big Dye Terminator Cycle Sequencing 
(Applied Biosystems), and the data were analyzed with Sequencing 
Analysis 3.0 software (Applied Biosystems). 
2.8. Real-time reverse transcriptase PCR analyses 
Cells were harvested at ~75% to 85% confluence and total RNA was 
isolated using mirVANATM miRNA Isolation Kit (Ambion, Life Science). 
FGFRs and other genes of interests were analyzed by Taqman-based 
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real-time PCR (ABI PRISM 7500; Applied Biosystems). The comparative 
CT method was used to determine relative gene expression for each 
target gene; the cyclophilin A gene was used as internal control to 
normalize the amount of amplifiable RNA. Taqman primers was 
purchased from Applied Biosystem as follows: E-cadherin, 
Hs00170423_m1; TP63, Hs00978343_m1; ZEB1, Hs00232783_m1; 
Vimentin, Hs00185584_m1; FGFR1, Hs00915142_m1; FGFR2, 
Hs01552926_m1; FGFR3, Hs00179829_m1; FGFR4, Hs01106908_m1; 
bFGF, Hs00266645_m; FABP4, Hs01086177_m1; CHOP, 
Hs00358796_g1; PPARa, Hs00947536_m1; PPARb, Hs04187066_g1; 
PPARg, Hs01115513_m1; GPX2, Hs01591589_m1; CYP2J2, 
Hs00951113_m1; ERRFI1, Hs00219060_m1; FRS2, Hs00183614_m1; 
FGFR3, Hs00179829_m1. 
2.9. Immunoblotting analyses 
Cells were harvested at ~75% to 85% confluence and lysed. Protein 
concentrations were measured using the Bradford assay (Bio-Rad 
Laboratories).  Lysates were boiled in sample buffer (62.5 mmol/L Tris-
HCl (pH 6.8), 10% (w/v) glycerol, 100 mmol/L DTT, 2.3% SDS, 0.002% 
bromophenol blue) for 5 minutes and cooled on ice for 5 minutes. Lysates 
were separated on 8% or 12% SDS-PAGE gels at 110 volts in 
electrophoresis buffer (25 mmol/L Tris-HCl (pH 8.3), 192 mmol/L glycine, 
0.1% SDS) and then electrophoretically transferred onto nitrocellulose 
membranes in transfer buffer (25 mmol/L Tris-HCl, 192 mmol/L glycine, 
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20% methanol) for 1 hour at 100 volts. The membranes were incubated in 
blocking buffer (5% nonfat milk in TBS: 10 mmol/L Tris-HCl (pH 8.0), 150 
mmol/L NaCl) for 1 hour at room temperature while shaking and then 
rinsed once briefly with TBS-T (TBS containing 0.1% Tween-20). The 
membranes were then incubated with primary antibodies diluted 1:1000 in 
blocking buffer overnight, washed, and then incubated with second 
antibodies (anti-rabbit immunoglobulin, horseradish peroxidase–linked 
F(ab)2 fragment from mouse) diluted 1:8,000 in blocking buffer for 1 hour 
at room temperature while shaking. Immunoreactive proteins were 
detected using enhanced chemiluminescence (Amersham Biosciences) 
according to the manufacturer’s instructions. 
2.10. Boyden chamber invasion assays 
Invasion chambers containing Matrigel-coated polyethylene terephthalate 
membranes with 8μm pores were purchased from BD BioSciences in a 
24-well plate format. Cells (2.5×105) were released from tissue culture 
flasks using EDTA (1 mmol/L), centrifuged, suspended in a serum free 
medium and placed in the upper compartments of invasion chambers. 
Thirty percent fetal bovine serum medium was placed in the lower 
compartments as a chemoattractant and invasion assays were carried out 
for 48 hours. Each cell line or condition was plated in triplicate. To 
examine cell invasion after exposure to BGJ-398, cells that had not 
invaded were removed and the cells on the lower surface of the filter were 
stained with Diff-Quick (American Scientific Products, McGaw Park, IL). 
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Invasive activity was measured by counting the cells that had migrated to 
the lower side of the filter. To evaluate invasion after silencing FGFR1 or 
bFGF, membranes were removed after incubation for 48 hours at 37°C 
and stained in propidium iodide (Sigma-Aldrich) without removing cells 
from the upper surfaces of the membranes. The filters were mounted on 
glass slides and analyzed by confocal microscopy at 100x magnification.  
The planes of focus were adjusted so that the cells that had not invaded 
could be distinguished from the invaded cells and counted in 8 
independent fields. Invasive activity was measured by calculating ratios of 
invaded to non-invaded cells. 
2.11. Gene silencing and exogenous overexpression 
For small interfering RNA (siRNA) silencing, cells were reverse-
transfected with siRNA using RNAiMAX (Invitrogen) according to the 
manufacturer’s guidelines and subjected to cell proliferation assays. In a 
parallel experiment, siRNA transfected cells were harvested at 48 hours. 
Total RNA and protein lysates were then analyzed for mRNA expression 
by RT-PCR and protein expression by immunoblotting to confirm target 
knockdown efficacy. 
For stable short hairpin RNA (shRNA) knockdown and Precision 
LentiORFs (pLOC) overexpression experiments, cells were plated in a 6-
well plates (105 cells/well) and transfected 24 hours later with the 
construct of interest.  Polybrene (Santa Cruz) was used to increase the 
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efficiency of infection. Cells were continuously cultured. Five days after 
transfection, fluorescence-activated cell sorting (FACS) was performed to 
isolate the GFP-positive transfected cells followed by puromycin or 
blasticidin selection. Total RNA and protein lysates were then collected to 
confirm efficacy of knockdown and overexpression respectively.  
2.12. Gene expression profiling analyses 
All transcriptome data were generated from triplicates. Total RNA of each 
replicate was isolated independently using mirVANATM miRNA Isolation 
Kit (Ambion, Life Technologies) and RNA purity and integrity were 
measured by NanoDrop ND1000 (Thermo Scientific) and Agilent 
Bioanalyzer (Agilent Technologies). High quality RNA was then used for 
the synthesis of biotin-labeled cRNA using the Illumina RNA amplification 
kit (Ambion) as described previously.  Briefly, 500 ng total RNA was 
converted to cDNA, then to cRNA by in vitro transcription, and finally 
purified. 1.5 μg cRNA was fragmented and hybridized to Illumina human-
HT12V4 chips (Illumina). The slides were washed, scanned with Bead 
Station 500 (Illumina), and the signal intensities were quantified using 
GenomeStudio (Illumina). Quantile normalization in linear models was 
used to normalize the data, which were processed by established 
techniques as described previously (citation).  
BRB ArrayTools (version 4.2, National Cancer Institute) was used to 
analyze the data. A class comparison tool within BRB ArrayTools was 
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used to identify top genes that were differentially expressed. The software 
uses a two-sample t test to calculate the significance of the observation 
with false discovery rate (FDR) (P < 0.001). To visualize expression 
patterns of genes, specific gene expression values were centered and 
adjusted to a mean of zero and then subjected for clustering with Cluster 
and TreeView (citation). Functional and pathway analyses were performed 
using the Ingenuity Pathway Analysis (IPA) software (Ingenuity System). 
The software contains a database for identifying networks and pathways 
of interest in genomic data. The “upstream regulator” analysis function 
was used to interpret the biological properties of gene profiling data. 
2.13. Animals study 
Female athymic nude mice (NCr-nu) were purchased from the National 
Cancer Institute. The mice were housed under specific pathogen-free 
conditions in the Animal Core Facility at The University of Texas M. D. 
Anderson Cancer Center. The facility has received approval from the 
American Association for Accreditation of Laboratory Animal Care and in 
agreement with current regulations and standards of the U.S. Department 
of Health and Human Services, the U.S. Department of Agriculture, and 
the NIH. The mice used in these experiments were 6 to 8 weeks old.  
2.14. Subcutaneous xenograft experiments 
Subcutaneous injections of UM-UC-9 and UM-UC-14 into the right flank 
were conducted using 106 cells/ 50μl Hank’s balanced salt solution 
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(HBSS) without calcium and magnesium. The tumors’ major and minor 
axes were measured with a caliper twice a week. The tumor volumes 
(mm3) were calculated using the formula: width2 × length / 2.  Tumors 
were allowed to establish for 5 days before being randomized into groups 
for experiments. 
2.15. Orthotopic xenograft experiments 
Human BC cell line UM-UC-3 was transduced with a lentiviral vector 
encoding luciferase (luc) and red fluorescent protein (RFP, mCherry) as 
described previously (citation). After stable transduction with the luc-RFP 
reporter, cells were sorted by Fluorescence Activated Cell Sorting (FACS) 
using an Influx High-Speed sorter (BD Biosciences).  Luciferase activity 
was quantified in vitro using d-luciferin (150 μg/mL) and the IVIS 
bioluminescence system (Xenogen Co.). To produce tumors in nude mice, 
sub-confluent cultures of labeled UM-UC3 were lifted with trypsin, mixed 
with 10% FBS MEM, centrifuged at 1,200 rpm for 5 min, washed in PBS, 
and resuspended in HBSS. Cells were then injected orthotopically into the 
bladder wall at a concentration of 5 × 105/50μL using a lower laparotomy. 
Mice bearing metastases were euthanized 5 to 8 weeks after tumor cell 
injection, the lymph node and distant metastases were excised, cut into 
small pieces using scalpels, exposed to 1% trypsin for 20 minutes, 
centrifuged (1,200 rpm for 5 min), and cultured in 10% supplemented 
MEM. After FACS sorting, the recycled cells were sub-confluently cultured 
and re-injected at a concentration of 2 × 105/50μL HBSS as described 
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above. Thus, tumor cell recycling was performed three times in order to 
select a highly metastatic UM-UC3 subpopulation which develops 
metastases in ~75% of mice. For our therapy experiment, we injected the 
4th cycle of recycled UM-UC3 at a concentration of 2 × 105/50μL. Mice 
with detectable tumor growth at the time of the first imaging (5 days after 
injection) were randomized into two groups (n = 7/group) and immediately 
were administrated either vehicle control (1% Tween-80) or BGJ-398 
(12.5 mg/kg) once daily by oral gavage. 
2.16. In vivo bioluminescence imaging 
Bioluminescence imaging was conducted on an IVIS 100 imaging system 
with Living Image software (Xenogen) as described elsewhere (citation). 
In brief, animals were anesthetized with a 2.5% isoflurane/air mixture 
before imaging and injected s.c. with 15 mg/mL of luciferin potassium salt 
in PBS at a dose of 150 mg/kg. A digital gray-scale animal image was 
acquired and a pseudo-colored image was overlaid representing the 
spatial distribution of detected photons emerging from active luciferase. 
Signal intensity was quantified as the sum of all detected photons within 
the region of interest per second, separately counting each primary tumor 
and each metastatic site. 
2.17. Collection of primary tumors and circulating tumor cells 
Forty days after injection, when animals in the control group became 
moribund, mice were anesthetized with isoflurane as described above. To 
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measure the number of circulating tumor cells (CTCs), the maximal 
amount of blood (600-1200μl) was collected by cardiac puncture using 1 
ml syringe, 22 gauge needle, and heparin-coated collection tubes as 
described previously. Mice were then euthanized with carbon monoxide. 
For further blood processing, red blood cells were lysed twice for 5 min 
with 10ml ACK lysis buffer (Invitrogen), and centrifuged for 5 min at 1200 
rpm in Eppendorf tubes. The pellet was finally lysed and further processed 
for total RNA isolation using the mirVANATM miRNA Isolation kit (Ambion, 
Life Science). To quantify the CTCs, absolute quantification of real-time 
PCR analysis (Step One; Applied Biosystems) was used to generate cycle 
threshold (CT) values for human specific HLA-C primer (Hs00740298_g1) 
for each sample. RT-PCR analysis of the blood samples was run alone 
with standard isolates (0, 2, 20, 200, 2000, and 20,000 UM-UC3 cells in 
100μl mouse blood). CT values of the standards were used to create a 
standard curve for UM-UC3 CTCs, and the number of CTCs of each blood 
sample was calculated accordingly. 
2.18. Statistics 
Statistical analysis was performed using GraphPad Prism Software 
(GraphPad). As appropriate, raw data or percentages were compared by 
unpaired Student’s t-test. Tumor growth curves in xenografts were 
analyzed using Two-Way ANOVA with Bonferroni multiple comparisons. 
Statistical significance was set at p < 0.05. 
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CHAPTER 3. FGFR1 AND FGFR3 MEDIATE 
DISTINCT FUNCTIONS IN HUMAN BLADDER 
CANCER GROWTH AND METASTASIS 
 
  
54 
 
3.1. Results 
3.1.1. Genome wide expression profiling of FGFRs and correlation 
with EMT markers. 
Our previous studies [115,147] revealed a binary pattern of heterogeneity 
in a panel of 30 urothelial cancer cells. More specifically, it was shown that 
UC cells can be grouped into two major categories in terms of biomarker 
expression, forming: “epithelial” and “mesenchymal” subsets. In this study, 
we first analyzed the expression of all four FGF receptors and the 
dominant cancer-associated FGF ligand, FGF2/basic FGF, at the mRNA 
level in the panel of 30 cell lines using whole genome expression profiling 
(Illumina HT12V4 Platform) and compared the pattern of FGFR/bFGF 
expression to markers of the “epithelial” and “mesenchymal” subsets. The 
expression of FGFR3 correlated with E-cadherin and p63 [148-150], which 
suggested FGFR3 was expressed by “epithelial” UC cells. In contrast, the 
expression of FGFR1 and FGF2 directly correlated with vimentin, a 
“mesenchymal” marker (Figure 3.1). To more accurately define the 
“epithelial” and “mesenchymal” subsets within the panel of UC cells, we 
then used quantitative real-time reverse transcriptase PCR (RT-PCR) to 
measure the expression of two “epithelial” markers (E-cadherin and p63) 
and two “mesenchymal” markers (Zeb-1 and vimentin) in the cells. As 
shown in the Figure 3.2, the expression of E-cadherin directly correlated 
with p63 expression while inversely correlating with expression of Zeb-1  
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Figure 3.1 Expression of FGFR1, FGFR3 and bFGF in distinct 
subsets of human urothelial cancer cells. Correlation of FGFR1, 
FGFR3 and bFGF with canonical EMT markers. mRNA levels were 
measured by whole genome mRNA expression profiling (Illumina). The 
heatmap illustrate the expression of FGFR1, FGFR3, FGF2, p63 (TP63), 
E-cadherin (CDH1), Slug (SNAI2) and vimentin (VIM). 
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Figure 3.2 Expression of EMT markers measured by RT-PCR. Relative 
levels of “epithelial” markers E-cadherin (CDH1) and p63 (TP63), and 
“mesenchymal” markers Zeb-1 (ZEB1) and vimentin (VIM) were measure 
by RT-PCR. Expression levels were normalized to UM-UC16. 
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and vimentin. These data indicated that the “epithelial” and 
“mesenchymal” markers are expressed in a non-overlapping manner 
among the majority of UC cell panel in that only two cell lines (UM-UC18 
and 1A6) co-expressed “epithelial” and “mesenchymal” markers (Figure 
3.2). 
3.1.2. Correlation between E-cadherin and FGFR/bFGF expression 
in urothelial cancer cells. 
To fully understand the relationship between EMT markers and 
FGFR/bFGF expression, we first examined expression of FGFRs1-4 and 
bFGF (FGF-2) by RT-PCR. In line with the gene expression profiling data, 
the expression of FGFR1 and FGF-2 were enriched in the “mesenchymal” 
subset (UM-UC3, UM-UC13, T24, BV and UM-UC12), whereas FGFR3 
was primarily expressed within “epithelial” subset (RT4, UM-UC14, RT112 
and SW780) (Figure 3.3). Although FGFR2 expression also appeared to 
be concentrated within the “epithelial” subset and FGFR4 expression in 
“mesenchymal” subset respectively, their levels of expression were lower 
than the levels of FGFR3, FGFR1 or bFGF, which is consistent with recent 
studies [103]. We then used nonparametric correlation analyses to confirm 
that expression of FGFR3 correlated strongly with E-cadherin expression 
(Spearman r=0.8155, p<0.0001, Figure 3.4) but inversely with expression 
of “mesenchymal” markers (Table 3.1). On the contrary, expression of 
FGFR1 and bFGF correlated strongly and directly with Zeb-1 expression  
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Figure 3.3 Expression of FGFRs 1-4 and bFGF.  The relative mRNA 
levels were measured by quantitative real-time RT-PCR.  The cell lines in 
each panel are organized by relative E-cadherin expression (low to high, 
from left to right, refer to Figure 3.2). 
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Figure 3.4 Relationship beteween FGFR/bFGF and EMT markers. 
Scatterplots depicting the relationships between expression of FGFR3, 
bFGF, FGFR1, and EMT markers. Nonparametric correlation analyses 
were used to evaluate the relationships between FGFR3 and E-cadherin 
(CDH1) expression, FGFR1 and ZEB1 expression, bFGF and ZEB1 
expression, and bFGF and FGFR1 expression.  Correlation coefficients 
and p values are indicated on the figure.   
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Table 3.1 Correlation between FGFR/bFGF and EMT markers. The 
figure displays the results of the nonparametric correlation analyses. 
Correlation coefficients are displayed in red, and corresponding p values 
are depicted in black.  Negative correlation coefficients indicate the 
presence of an inverse relationship between markers. 
 
 
 
 
  
Spearman correlation 
*
R value, 
#
P value  
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(Spearman r=0.799, p=0.0001 for FGFR1 and r=0.6198, p=0.008 for 
bFGF, Figure 3.4). In addition, FGFR1 and bFGF correlated directly with 
each other as we expected (Figure 3.4). We then investigated whether the 
pattern of differences observed in mRNA level could be translated into 
protein level in a subset of the cell lines by immunoblotting. We found that 
FGFR3 but not FGFR1 was expressed in “epithelial” cell lines UM-UC14, 
RT112 and RT4. Conversely, FGFR1 but not FGFR3 was expressed in 
“mesenchymal” cell lines UM-UC3, UM-UC12 and UM-UC13. Although 
bFGF was expressed in all 6 cell lines, “mesenchymal” cell lines (UM-
UC3, UM-UC12 and UM-UC13) indeed expressed more bFGF than 
“epithelial” cell lines (UM-UC14, RT112 and RT4) (Figure 3.5). Together, 
these data suggested that FGFR1/bFGF and FGFR3 probably drive 
separate functions in non-overlapping “mesenchymal” and “epithelial” UC 
cells. 
3.1.3. Effects of BGJ-398 on proliferation. 
Recent studies indicated that FGFR inhibition blocks cell proliferation in 
human UC cells [104,126]. We therefore examined the effects of BGJ-398 
on proliferation in 17 UC cell lines to characterize the scale of 
heterogeneity of drug sensitivity. Cells was incubated with increasing 
concentration of BGJ-398 for 48 hours and then subjected to MTT assay 
to measure drug induced cytotoxicity and/or growth arrest. We identified 4 
cell lines (UM-UC14, SW780, RT4 and RT112) that were drug sensitive as 
≥50% growth inhibition at concentrations of 1μM or lower (Figure 3.6A). 
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Figure 3.5 Baseline expression of FGFR1, FGFR3 and bFGF proteins 
in subsets of epithelial and mesenchymal UC cells. FGFR1, FGFR3 
and bFGF in 3 representative “epithelial” (UM-UC14, RT4 and RT112) and 
3 “mesenchymal” (UM-UC3, UM-UC12 and UM-UC13) cell lines were 
measured by immunoblotting. 
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A. 
 
B.  
 
Figure 3.6 Effects of BGJ-398 on cell proliferation in the drug-
sensitive cells.  A. cells were incubated for 48 h in the presence of the 
indicated concentrations of BGJ-398 and cell growth was measured by 
MTT reduction.  Mean ± SEM, n = 6.  B. UM-UC14 or RT4 cells were 
incubated with the indicated concentrations of BGJ-398 and the 
percentages of cells within each cell cycle quadrant were quantified by 
propidium iodide staining and FACS analysis.  Mean ± SEM, n = 3.   
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To further determine the relative contribution of cell death versus growth 
arrest to these effects, we directly measured cell cycle arrest and 
apoptosis by propidium iodide (PI) staining and FACS analysis after 
exposing UM-UC14 and RT4 cells to increasing concentration of BGJ-398 
for 48 hours. We observed increases in percentage of cells in G1 phase 
whereas a decreases in percentage of cells in S phase in both cell lines 
with increasing concentrations of BGJ-398. More specifically, the 
percentage of cells in G1 phase increased from 47.5% and 54% to 74.2% 
and 69.1%, and in parallel the percentages of cells in S phase decreased 
from 33.5% and 25% to 2.7% and 8.8%, in the BGJ-398 treated UM-UC14 
and RT4 respectively (Figure 3.6B). On the contrary, BGJ-398 exposure 
did not cause any apoptosis at concentration lower than 10 μM in either of 
the cell lines (data not shown). These data indicated that BGJ-398 
induced cytostatic effects on UC cells in vitro. 
Recent studies revealed FGFR3 activating mutations and overexpression 
as potential mechanisms contributing to response to FGFR antagonist 
[64,151]. We therefore examined the relationship between BGJ-398 
sensitivity and the presence of activating FGFR3 mutations. We first 
identified 5 cell lines (UM-UC6, UM-UC14, UM-UC15, UM-UC16 and UM-
UC17) that contained activating FGFR3 mutations within our panel by 
exon sequencing (Table 3.2). Strikingly, only one of the 5 cell lines was 
BGJ-398 sensitive. However, FGFR3 mRNA expression correlated 
strongly with drug sensitivity using nonparametric correlation analysis  
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Table 3.2 FGFR3 mutation status in human bladder cancer cells. The 
presence of activating FGFR3 mutations was determined by exon 
sequencing.  Note that among the 5 cell lines within the panel that contain 
activating mutations, only one (UM-UC14) is sensitive to BGJ-398. 
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(Spearman r=0.7247 p=0.01, Figure 3.7), whereas no clear correlation 
was observed between FGFR1 mRNA expression and sensitivity to BGJ-
398 (Spearman r=-0.2931 p=0.2536, Figure 3.9) 
Given the non-overlapping pattern of FGFR3 and FGFR1 expression, the 
indicated results suggested that FGFR3 was more essential than FGFR1 
in driving cell proliferation in “epithelial” UC cells. We then used RNAi to 
directly test this hypothesis. BGJ-398 sensitive cells were transfected with 
either FGFR3 or FGFR1 siRNAs to knock down the targeted gene and cell 
proliferation was measured by MTT assay. Quantitative PCR confirmed 
FGFR3 knockdown efficiencies of 50% and >80% in the RT4 and UM-
UC14 with FGFR3 siRNAs compared to non-specific siRNA control, 
respectively. The result was also confirmed by Immunoblotting at protein 
level (Figure 3.8). The corresponding effect of FGFR3 silencing was very 
similar to BGJ-398 exposure. Cell proliferation was reduced by 60% 
and >90% in RT4 and UM-UC14 cells transfected with FGFR3 siRNA, 
respectively (Figure 3.9). Cell cycle analyses revealed that FGFR3 
knockdown increased the percentage of cells in G1 phase and decreased 
the percentage of cells in G2 phase, which is consistent with the MTT 
results. However, FGFR1 silencing had no significant effect on 
proliferation and cell cycle in both RT4 and UM-UC14(Figure 3.10). 
 
 
67 
 
 
 
 
Figure 3.7 Sensitivity to the anti-proliferative effects of BGJ-398 
correlates with FGFR3 expression but not with the presence of 
activating FGFR3 mutations.  The level of growth inhibition observed 
after 48 h exposure to 1 μM BGJ-398 (as measured by MTT assays) was 
correlated with the relative level of FGFR3 (left panel) or FGFR1 (right 
panel) mRNA expression in a panel of 17 human BC cell lines. 
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A. 
 
B. 
 
 
Figure 3.8 Efficiency of FGFR3 silencing measured by quantitative 
RT-PCR and immunoblotting. A. measurement of FGFR3 silencing 
efficiency by quantitative PCR. B. measurement of FGFR3 silencing 
efficiency by immunoblotting. 
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A. 
 
B. 
 
Figure 3.9 Effects of FGFR3 knockdown on cell proliferation.  UM-
UC14 or RT4 cells were transiently transfected with either non-targeting 
(NT) or FGFR3-specific siRNAs and, A. cell growth was measured at 48 h 
by MTT reduction.  Mean ± SEM, n = 6. B. percentages of cells within 
each phase of the cell cycle were quantified by propidium iodide staining 
and FACS analysis.  Mean ± SEM, n = 3.   
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Figure 3.10 Effects of FGFR1 knockdown on FGFR1 expression and 
proliferation in RT4 and UM-UC14 cells. UM-UC14 or RT4 cells were 
transiently transfected with either non-targeting (NT) or FGFR1-specific 
siRNAs and, cell growth was measured at 48 h using MTT.  Mean ± SEM, 
n = 8. And, the percentages of cells within each phase of the cell cycle 
were quantified by propidium iodide staining and FACS analysis.  Mean ± 
SEM, n = 3.   
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3.1.4. Effects of BGJ-398 on invasion. 
Our data indicated the “mesenchymal” UM-UC3 and UM-UC13 were 
resistant to the growth arrest effect of BGJ-398 (Figure 3.11A) although 
both of they expressed relatively high levels of FGFR1. Given that 
migration, invasion and metastasis are key characters of “mesenchymal” 
cells [150], we examined the effects of BGJ-398 on invasion in UM-UC3 
and UM-UC13 while two “epithelial” BGJ-398 resistant cells (UM-UC6 and 
UM-UC9) were used as controls. The cells were exposed to increasing 
concentrations of BGJ-398 and invasion was measured using modified 
Boyden chambers. BGJ-398 effectively inhibited invasion in the 
“mesenchymal” UM-UC3 and UM-UC13 cells in a concentration 
dependent manner but not in the “epithelial” UM-UC6 and UM-UC9 cells 
(Figure 3.11B). 
Because our previous data suggested a direct correlation between 
bFGF/FGFR1 and “mesenchymal” markers (Figure 3.3), we then 
hypothesized that bFGF/FGFR1 are involved in the regulation of invasion 
in “mesenchymal” cells. To directly test the hypothesis, we first transfected 
UM-UC3 and UM-UC13 cells with lentiviral shRNAs to stably silenced the 
expression of either bFGF or FGFR1. The efficiency of targeted 
knockdown was confirmed by both quantitative PCR at mRNA level and 
immunoblotting at protein level (Figure 3.12). We then quantified invaded 
cells in these bFGF/FGFR1 stably silenced cells and compared it to the 
results from non-specific control and parental cells using modified Boyden 
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A. 
 
B. 
 
Figure 3.11 Effects of BGJ-398 on cell growth and invasion in two 
“mesenchymal’ (UM-UC3, UM-UC13) and two “epithelial” (UM-UC6, 
UM-UC9) cell lines. Growth inhibition was measured at 48 h by MTT 
reduction.  Mean ± SEM, n = 6.  Invasion was measured using modified 
Boyden chambers and standard light microscopy as described in Materials 
and Methods.  Mean ± SEM, n = 3.   
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A.  
B. 
 
Figure 3.12 FGFR1 or bFGF silencing in cells transduced with 
lentiviral shRNAs.  A. Relative mRNA levels were measured by 
quantitative real-time RT-PCR and B. protein levels were measured by 
immunoblotting.   
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chambers and confocal microscopy.  In UM-UC3 cells, the percentage of 
invading cells was reduced from 85% in the parental cells or cells 
transduced with a control lentiviral construct to 54.5% in bFGF KD cells 
(P=0.0029) and 63.8% in FGFR1 KD cells (P=0.0038), respectively. 
Similarly, in UM-UC13 cells, the levels of invasion were reduced from 82% 
in parental cells or cells transduced with the non-targeting lentivirus to 
64.8% in the bFGF KD cells (P=0.0146) and 52.4% in FGFR1 KD cells 
(P=0.0018) (Figure 3.13). Together, the data confirmed that bFGF and 
FGFR1 both promoted invasion in “mesenchymal” BC cells. 
3.1.5. Effects of BGJ-398 on tumor growth and metastasis. 
Although in vitro models are excellent tools for studying molecular 
mechanisms, the process of cancer metastasis is regulated by tumor-
stromal interactions that cannot be modeled well in vitro. Therefore, in 
order to better define the effects of BGJ-398 on primary tumor growth 
versus metastasis in “mesenchymal” BC cells, we first isolated a highly 
metastatic form of UM-UC3 using orthotopic “recycling” in nude mice 
[152].  We transduced the cells with a lentiviral vector encoding luciferase 
and red fluorescent protein (RFP), which enabled us to monitor primary 
tumor growth and metastasis non-invasively by luciferase imaging and to 
isolate circulating tumor cells (CTCs) by cell sorting.  After 3 rounds of 
recycling, the UM-UC3 cells formed orthotopic tumors in 100% of mice 
and consistently produced metastases to lymph nodes, lungs, and bone in 
over 70% of mice.  We then implanted 200,000 of the recycled UM-UC3  
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Figure 3.13 Effects of FGFR1 or bFGF silencing on invasion.  The 
percentages of cells that invaded through Matrigel in modified Boyden 
chambers were quantified by propidium iodide staining and confocal 
microscopy. Representative confocal images were displayed at right panel 
where the nuclei of the cells that invaded are pseudo-colored blue and the 
cells that did not invade are depicted in red.  
  
76 
 
cells orthotopically in nude mice and initiated therapy with BGJ-398 or 
vehicle (via oral gavage) once primary tumors were well established (on 
day 8), monitoring tumor growth and metastasis biweekly by IVIS imaging 
(Figure 3.14; 3.15).  Interestingly, primary tumors in the mice treated with 
BGJ-398 appeared to grow slightly faster than controls, although the 
differences in growth rates were not statistically significant (Figure 3.14; 
P>0.05). In contrast, BGJ-398 strongly inhibited the development of 
metastases and CTCs.  Specifically, 5 out of 7 mice within the control 
group developed lymph node metastasis by day 15, and two of these 
subsequently developed bone and lung metastasis at day 36 (Fig. 3.15 
right panel). However, we detected only 1 lymph node metastasis in the 7 
animals within the BGJ-398 treatment group.  When we quantified total 
metastatic burden using luciferase imaging, the differences between the 
vehicle and BGJ-398 treatment groups were highly significant (Figure 
3.15; p = 0.0078).  Finally, we quantified the numbers of circulating tumor 
cells in the mice at the time of sacrifice on day 40 by measuring human 
HLA-C levels in whole peripheral blood by quantitative PCR. CTC 
numbers within the control group ranged from 325 to 336,008 cells (mean 
= 158,977), whereas CTC numbers in the treated group ranged from 160 
to 370 (mean = 243.6) (Figure 3.16; p < 0.01).  Together, the results 
demonstrated that BGJ-398 had no inhibitory effect on the growth of UM-
UC3 primary tumors but did block tumor cell extravasation into the 
vasculature (as measured by CTC production) and metastasis. 
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Figure 3.14 Effects of BGJ-398 on primary tumor growth in mice 
bearing orthotopic UM-UC3 xenografts. Luciferase-labelled, 
orthotopically recycled UM-UC3 cells were implanted into the bladders of 
nude mice, and tumors were allowed to grow for 8 days prior to initiating 
therapy with BGJ-398 (daily via oral gavage).  Tumor growth was 
measured biweekly by luciferase imaging.  Mean ± SEM from 6 (control) 
or 7 (treated) mice per group.   
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Figure 3.15 Effects of BGJ-398 on metastasis in mice bearing 
orthotopic UM-UC3 xenografts.  Whole animal metastatic burdens were 
determined non-invasively by luciferase imaging.  Mean ± SEM, n = 6 
(control mice) or 7 (treated mice). Representative whole body luciferase 
images taken just prior to the initiation of therapy and at the conclusion of 
the experiment were displayed at right panel.   
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Figure 3.16 Effects of BGJ-398 on UM-UC3 CTC production.  CTC 
numbers were estimated by measuring human HLA levels in isolated 
whole blood by quantitative PCR; cell numbers were determined using a 
UM-UC3 standard curve.  The scatterplot displays the results obtained 
from each animal; the lines denote the mean values for each group. 
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Figure 3.17 Effects of bFGF or FGFR1 silencing in long-term 
proliferation assays. MTT results obtained in 5-day assays.  Mean ± 
SEM, n = 6.  *p<0.05. 
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3.2. Discussion 
FGFR3 is frequently activated by mutation [42,151,153] in both muscle 
invasive and non-invasive urothelial cancers, where it appears to drive cell 
proliferation [101,102]. Recent studies also revealed the prevalence of 
FGFRs overexpression, specifically overexpression of FGFR1 [103] and 
FGFR3 [154,155], which may identify as oncogenic addiction in urothelial 
cancer. Taken together, these data identify FGFR1 and FGFR3 as two of 
the most attractive targets in clinical development in bladder cancer 
[105,154]. However, there exists a significant heterogeneity in response to 
FGFR inhibitors [64,156-158] in BC cells based on the results published to 
date, and it is presently unclear what factors are driving sensitivity to 
FGFR inhibitors. The heterogeneity and the unclear underlying 
mechanisms could significantly jeopardize the identification of the 
appropriate subset of BC patients who could benefit markedly from the 
FGFR targeted therapy. 
Based on recent studies, it is likely that FGFR3 activating mutation (i.e. 
S249C) determines the FGFR3 dependency which drives the sensitivity to 
selective and non-selective FGFR inhibitors. However, in this study, our 
data demonstrated that the presence of an FGFR3 activating mutation 
alone does not predict sensitivity to BGJ-398 in a panel of human UC 
cells. Conversely, FGFR3 mRNA expression levels did correlate well with 
the sensitivity to BGJ-398 (Figure 3.7), suggesting a link between FGFR3 
overexpression and FGFR3 dependency. More specifically, among BC 
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cell lines bearing FGFR3 activating mutations, the majority of them were 
not sensitive to BGJ-389 in this study (UM-UC6, UM-UC15, UM-UC16, 
UM-UC17) or other FGFRs inhibitors (94-10, 97-18, J82) [156,158], 
though only two of them were highly sensitive to BGJ-398 or other 
inhibitors [156,157]. In contrast, at least one FGFR3 wild-type cell line 
(UM-UC1) was as sensitive to BGJ-398 as the most sensitive FGFR3 
mutant cells [156]. In addition, two other cell lines (RT4, RT112) bearing 
the FGFR3-TACC3 translocation were among the cell lines that are 
sensitive to BGJ-398. Although little is unknown about the underlying 
mechanism regarding this heterogeneity, a recent study provided a 
possible explanation, where FGFR3 mutant cells exhibited an escape 
mechanism through pathway redundancy to rescue the proliferation 
refractory from FGFR inhibition [132]. 
More importantly, our results indicated a non-overlapping pattern between 
FGFR3 and FGFR1 expression in the panel of human BC cells we 
studied, and interesting, cells with high expression level of FGFR1 were all 
relatively resistant to BGJ-398. Collectively, these data demonstrated that 
FGFR3 expression is a more important determinant than FGFR1 
expression in driving cell proliferation in the specific cells we studied. In 
addition, our data demonstrated that the primary effects of FGFR inhibition 
by BGJ-398 are cytostatic rather than cytotoxic, which indicated the 
potential value of FGFR inhibition lies in the combination with conventional 
chemotherapy or radiation therapy in clinical development. Indeed, in 
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future studies we are going to examine the hypothesis that FGFR 
inhibition could improve the effect of conventional chemotherapy or 
radiation therapy by promoting their cytotoxic effects. With respect to 
clinical development, it is worth noting that all of the human UC cell lines 
with a possible exception of RT4 are derived from muscle invasive UC. 
Due to this limitation, it is possible that the cell line studies underestimate 
the potential efficacy of FGFR3 inhibition in non-muscle invasive UCs. In 
fact, a majority of non-muscle invasive BC contain FGFR3 activating 
mutations, strongly suggesting that FGFR antagonists could have strong 
clinical activity in them. 
Interestingly, our data also demonstrated that FGFR1 played a significant 
role in cell invasion and tumor metastasis even though FGFR1 was less 
important than FGFR3 in promoting cell proliferation. More specifically, 
FGFR1 signaling repression by either BGJ-398 or specific FGFR1 
silencing led to reduced cell invasion in vitro (Figure 3.11, 3.13). In 
addition, BGJ-398 inhibited CTC production and metastasis without 
decreasing primary tumor growth in vivo (Figure 3.14, 3.15, 3.16), which 
seems to contradict a recent study suggesting the role of FGFR1 in driving 
both cell proliferation in vitro and tumor growth in vitro. However, our 
conclusion that FGFR1 did not drive cell proliferation in some 
“mesenchymal” UC cells was based on MTT assay to measure short-term 
effects of BGJ-398. We reached to the same conclusion that was 
advanced in previous work (blocking FGFR1 impaired cell proliferation) 
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when we measured long-term effects of stable silencing FGFR1 using 
colony formation assays (Figure 3.17), which indicated the importance of 
FGFR1 for initiation but not maintenance of cell proliferation in UC cells. 
Furthermore, our in vivo experiment was based on FGFR targeted therapy 
by BGJ-398 in mice with established orthotopic tumors whereas the 
previous work relied on stable silencing of FGFR1, consistent with the 
idea that FGFR1 is important for tumor initiation but may be not for 
maintenance of tumor growth. It is also worth noting that several other 
studies also suggested a role of FGFR1 in cell invasion and tumor 
metastasis [104]. 
Finally, our results demonstrated distinct effects of FGFR inhibition, in that 
FGFR3 inhibition blocked cell proliferation, whereas FGFR1 inhibition 
suppressed cell invasion and metastasis. It is presently unclear why the 
differential effects exist given that the effects on proliferation and invasion 
were clearly linked to inhibition of the same signal transduction pathway 
(MAPK/Erk signaling) [47,49,104]. One possible explanation was that the 
different effects are a consequence of the distinct biological difference 
between the epithelial and mesenchymal phenotype. Our data suggested 
a non-overlapping expression pattern of FGFR1 versus FGFR3 in UC cell 
lines in that FGFR1 primarily expressed in mesenchymal phenotype, 
whereas FGFR3 correlated well in epithelial phenotype (Figure 3.1, 3.2, 
3.3). It is highly possible that the “epithelial” cells are more dependent on 
autocrine growth factors for G1/S transition and proliferation than 
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“mesenchymal” cells, whereas the “mesenchymal” cells rely on growth 
factors for invasion rather than other cell functions. Our results also shed 
the light on possible clinical translation in muscle invasive urothelial 
tumors or where a subset of low grade non-muscle invasive urothelial 
tumors progress into muscle-invasive tumors. FGFRs inhibition in 
conjunction with conventional chemotherapy could be valuable to target 
these tumors and benefit patient sub-groups if appropriate biomarkers can 
be identified and deployed to pinpoint the subsets of tumors. 
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CHAPTER 4. A PPARγ-FABP4 TRANSCRIPTIONAL 
COMPLEX REGULATES EGFR DEPENDENCY IN 
HUMAN BLADDER CANCER CELLS 
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4.1. Result 
4.1.1. Sensitivity to EGFR or FGFR inhibitors is confined to the 
“epithelial” subset of bladder cancer (BC) cell lines  
Previous studies showed that 5 urothelial cancer (UC) cell lines (UM-UC4, 
UM-UC5, UM-UC7, UM-UC9 and UM-UC16) were sensitive to EGFR 
inhibitor gefitinib at clinically relevant concentration (≤ 1μM) in a panel of 
25 human urothelial cancer cell lines [115,147]. A recent screening of the 
FGFR inhibitor BGJ-398 in the same panel also identified 4 different cell 
lines (UM-UC14, SW780, RT4 and RT112) that were sensitive at clinically 
relevant concentration (≤ 1μM) [70]. We first confirmed that the same cell 
lines were sensitive to the structurally distinct FGFR inhibitor AZD4547 but 
not EGFR inhibitor gefitinib using both MTT assay (Figure 4.1) and 
thymidine incorporation assay (Figure 4.2). We also confirmed that the 
other 4 UC cell lines (UM-UC4, UM-UC5, UM-UC7, UM-UC9) were still 
sensitive to the EGFR inhibitor gefitinib but not FGFR inhibitor AZD4547 
as measured by both MTT assay (Figure 4.1) and thymidine incorporation 
assay (Figure 4.2). In addition, we also tested drug responses in vivo to 
further verify the observation. We found that UM-UC9 subcutaneous 
xenografts were sensitive to gefitinib and that UM-UC14 subcutaneous 
xenografts were sensitive to AZD4547 in vivo. The in vivo effects of the 
drugs were associated with decreased proliferation as measured by Ki-67 
immunohistochemistry (Figure 4.3). 
88 
 
 
Figure 4.1 Differential effects of the FGFR inhibitor AZD4547 and the 
EGFR inhibitor gefitinib in human UC cells. The human UC lines UM-
UC4, UM-UC5, UM-UC7, UM-UC9, UM-UC14, RT4, RT112, and SW780 
were exposed to either AZD4547 or gefitinib at the indicated 
concentrations, and cell proliferation was measured by MTT assays, 
normalized to controls (mean ± SEM). 
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Figure 4.2 Differential effects of the FGFR inhibitor AZD4547 and the 
EGFR inhibitor gefitinib in human UC cells. The human UC lines UM-
UC4, UM-UC5, UM-UC7, UM-UC9, UM-UC14, RT4, RT112, and SW780 
were exposed to either AZD4547 or gefitinib at the indicated 
concentrations, and cell proliferation was measured by thymidine 
incorporation assay, normalized to controls (mean ± SEM). 
 
 
  
90 
 
 
Figure 4.3 Growth inhibition of gefitinib or AZD4547 in subcutaneous 
xenograft models. UM-UC9 and UM-UC14 cells were injected 
subcutaneously into nude mice. Tumors were allowed to establish for 5 
days prior to treatment with either vehicle (control) or gefitinib (UM-UC9; n 
= 12 / group) or AZD4547 (UM-UC14; n = 9 / group) via oral gavage. 
Tumor volumes (mm3) were calculated using the formula width2 x length / 
2, and depicted as means ± SEMs. Tumor tissue was harvested, fixed and 
stained for Ki-67 using immunohistochemistry. 
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These results suggested that sensitivity to either gefitinib or AZD4547 
were confined to an ‘epithelial’ subset of UC cell lines characterized by 
high levels of E-cadherin expression (an epithelial marker) [70,147] and 
that sensitivity to either drug was mutually exclusive. Specifically, all of the 
cell lines that were sensitive to gefitinib were resistant to AZD4547, and all 
of the cell lines that were sensitive to AZD4547 were resistant to gefitinib 
(Figure 4.1 and 4.2). We then confirmed these in vitro results using 
orthotopic in vivo models by conducting four-arm studies in UM-UC9 (n 
=11 / group) and UM-UC14 (n = 9 / group) tumor-bearing nude mice. 
Consistent with the in vitro results, we found that once-daily oral 
administration of gefitinib (12.5 mg/kg) produced strong tumor growth 
inhibition in UM-UC9. On the contrary, AZD4547 (12.5 mg/kg) had no 
effect on tumor growth by itself. In addition, the combination of gefitinib 
and AZD4547 (each at 12.5 mg/kg) did not result in any additional effect 
(Figure 4.4, upper left panel). Conversely, AZD4547 but not gefitinib (each 
at 12.5 mg/kg) produced strong growth inhibition in the orthotopic UM-
UC14 tumors. In addition, combination of AZD4547 and gefitinib produced 
no added benefit as compare to single agent therapy with AZD4547 
(Figure 4.4, lower left panel). Measurements of tumor weights at sacrifice 
(after 4 weeks of therapy) confirmed the imaging results (Figure 4.4, right 
panel). Together, these date indicated sensitivity to either EGFR or FGFR 
inhibitor is non-overlapping and mutually exclusive both in vitro and in  
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Figure 4.4 Effects of AZD4547, gefitinib, and AZD4547 plus gefitinib 
on the tumor growth of orthotopic xenografts. Luciferase-labeled UM-
UC9 and UM-UC14 were orthotopically implanted into the bladders of 
nude mice. Tumors were allowed five days to establish prior to treatment. 
Animals were given AZD4547 (12.5mg/kg), gefitinib (12.5mg/kg), or a 
combination of both TKIs (12.5mg/kg each), or vehicle control (1% Tween 
80, 99% deionized water) once daily for four weeks by oral gavage (n = 9 / 
group). Tumor growth was repeatedly measured non-invasively by in vivo 
bioluminescence imaging. The results are expressed as photon counts 
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(mean ± SEM). In addition, UM-UC9 and UM-UC14 primary tumors were 
harvested at sacrifice and weighed after four weeks of treatment. Tumor 
weights (mg) are indicated as means ± SEM. 
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vivo. Therefore, we identified 4 UC cell lines (UM-UC14, SW780, RT4 and 
RT112) as FGFR dependent and another discrete 4 cell lines (UM-UC4, 
UM-UC5, UM-UC7, UM-UC9) EGFR dependent within the panel. 
We also noticed that several of the UC cell lines that contain activating 
FGFR3 mutations are resistant to FGFR inhibitors in vitro such as UM-
UC6  [70]. Since three-dimensional growth and/or the tumor 
microenvironment could have major effects on drug sensitivity [159], we 
examined the effects of AZD4547 on orthotopic tumors (n = 8 mice / 
group) derived from the ‘epithelial’ UM-UC6 cells, which contain an 
activating S249C mutation but are resistant to FGFR inhibitors in vitro [70]. 
We observed that AZD4547 alone had no effect on tumor growth (Figure 
4.5), confirming and extending our previous conclusion that FGFR3 
mutational status alone is not predictive of FGFR inhibitor sensitivity [70]. 
4.1.2. Sensitivity to AZD4547 correlates with A-FABP/FABP4 
expression 
To determine the biological mechanisms underlying the differential 
sensitivities of UC cells to AZD4547 and gefitinib, we performed mRNA 
expression profiling using the Illumina platform (Human HT-12 V 4.0) to 
compare the baseline mRNA expression profiles in the FGFR- and EGFR- 
dependent UC cells. We found that several of the top genes that were 
differentially expressed between them were components of the PPARγ 
transcriptional pathway (Figure 4.6). Specifically, high baseline expression  
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Figure 4.5 Effects of AZD4547 in orthotopic UM-UC6 tumors. UM-UC6 
cells were orthotopically implanted into the bladder. Tumors were allowed 
five days to establish prior to treatment. Animals were given either vehicle 
or AZD4547 (12.5 mg/kg) via oral gavage (n = 8 / group). Primary tumor 
growth was continuously measured by non-invasive in vivo 
bioluminescence imaging. Photon counts are indicated as mean ± SEM. 
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Figure 4.6 Differential expression of FABP4, CYP2J2, GPX2 and 
FGFR3 in a panel of urothelial cancer cell lines (n = 25). Whole 
genome mRNA expression profiling (Illumina platform) was used to 
measure mRNA expression. The heat map depicts the expression of 
CYP2J2, FABP4, GPX2 and FGFR3. Urothelial cancer cell lines are color-
coded according to the corresponding sensitivity to gefitinib (blue) or 
AZD4547 (red). 
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of fatty acid binding protein 4 (FABP4, Adipocyte-FABP), characterized 
the FGFR-dependent cell lines, whereas FABP4 was essentially 
undetectable in the EGFR-dependent cells (a 55-fold difference) (Figure 
4.6). We confirmed these findings by both quantitative PCR and 
Immunoblotting (Figure 4.7). Additionally, the FGFR-dependent cells 
expressed high levels of CYP2J2 (7-fold difference), the cytochrome P450 
isoform that produces PPAR ligands [160], and GPX2 (18 fold difference), 
a known downstream target of PPARγ signaling [160,161] (Figure 4.6). 
These results were also confirmed by quantitative PCR (Figure 4.8).  To 
further validate that the FGFR-dependent cells displayed baseline gene 
expression patterns consistent with PPARγ activation, we then used a 
hepatocyte-derived PPARγ gene set [162] to conduct gene set enrichment 
analyses (GSEA) to test degree of PPARγ signal enrichment in the FGFR-
dependent cells as compared to the EGFR-dependent cells. The results 
indicated that PPARγ regulating genes were enriched in the FGFR-
dependent cells with a normalized enrichment score (NES) of 1.83 (Figure 
4.9, P=0.002). Together, these results suggested a strong correlation 
between PPARγ activation, more specifically constitutive expression of 
FABP4  
4.1.3. PPARγ modulates FABP4 expression in UC cells 
FABP4 functions as a specific co-activator for PPARγ by binding PPARγ 
ligands in the cytosol, transferring and facilitating ligand binding to PPARγ 
via a mechanism that has been termed “ligand tunneling”, and promoting  
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Figure 4.7 Confirmation of differential FABP4 expression in the panel 
of UC cells. FABP4 mRNA and protein expression were measured by 
quantitative PCR and immunobloting respectively. 
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Figure 4.8 Expression of CYP2J2 and GPX2 in the EGFR (UM-UC4, 
UM-UC5, UM-UC7, UM-UC9) and FGFR (UM-UC14, RT4, RT112, 
SW780) dependent UC cell lines. CYP2J2 and GPX2 mRNA expression 
was measured by quantitative PCR and normalized to UM-UC9.  
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Figure 4.9 Hepatocyte-derived PPARγ gene set is enriched in FGFR3-
dependent cells. Gene set enrichment analyses were performed to 
compare PPARγ pathway gene expression in the four FGFR3-dependent 
(UM-UC14, RT4, RT112, SW780; red color coded) and the four EGFR-
dependent (UM-UC4, UM-UC5, UM-UC7, UM-UC9; blue color coded) cell 
lines using the whole genome mRNA expression profiling data. 
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PPARγ translocation to the nucleus [163,164]. Although GSEA indicated 
the activation of PPARγ transcriptional pathway in FGFR dependent UC 
cells that were featured constitutive expression of FABP4, it was unclear 
whether PPARγ was in fact responsible for this constitutive FABP4 
expression in the FGFR dependent cells because of the fact that all three 
PPAR isoforms (α, β, γ) interact with similar DNA response elements 
[165]. Therefore, we first used isoform-specific chemical agonists to 
determine this. Exposure to the PPARγ-selective agonist rosiglitazone but 
not the α- and β-isoform agonists Wy14643 and L-165,041 resulted in 
strong induction of FABP4 in the EGFR-dependent cells (Figure 4.10 
upper panel). We observed similar but less substantial effects in the FGFR 
dependent cells, most likely because they expressed higher levels of 
FABP4 at baseline (Figure 4.10 lower panel). None of the three isoform-
selective antagonists had any effects on FABP4 expression in the 
absence of ligand (data shown for PPARγ, Figure 4.10). However, siRNA 
mediated silencing of PPAR (but not the other isoforms) inhibited basal 
FABP4 expression in the FGFR dependent cell lines UM-UC14 and RT4 
(Figure 4.11). Taken together, these data suggested that the constitutive 
high-level expression of FABP4 observed in the FGFR dependent UC 
cells is caused by constitutive PPARγ activation. 
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Figure 4.10 FABP4 expression is regulated by PPARγ. EGFR 
dependent bladder cancer cells (UM-UC4, UM-UC5, UM-UC7, UM-UC9) 
were exposed to the selective PPARγ agonist rosiglitazone and FABP4 
mRNA expression was measured by quantitative RT-PCR. Modulation of 
FABP4 mRNA levels by the PPARγ agonist rosiglitazone and the PPARγ 
antagonist GW9662 in FGFR3 dependent bladder cancer cells (UM-UC14, 
RT4). 
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A.  
B.  
 
Figure 4.11 Effects of silencing PPARα, β or γ isoform on FABP4 
expression. A. Knockdown efficacy of siRNAs specific for different PPAR 
isoforms. B. FABP4 expression after PPARα, β or γ knockdown.  Relative 
mRNA expression was measured by quantitative PCR. 
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4.1.4. Modulation of FABP4 affects EGFR sensitivity 
Recent publication suggests that FABP4 is an obligate co-activator for 
PPARγ activation, in that FABP4 binds and delivers PPARγ ligands from 
cytosol to nucleus, therefore facilitating the ligation and enhancing the 
transcriptional activity of PPARγ [163,164]. Additionally, our data revealed 
that FGFR dependent cells are characterized by the constitutive PPARγ 
activation, whereas little/low level of PPARγ activation marks the EGFR-
dependent cells. Therefore, we tried to determine whether PPARγ 
activation affected FGFR and/or EGFR inhibitor sensitivity. We first 
exposed the EGFR dependent cell lines to rosiglitazone with or without 
gefitinib and measured growth inhibition using 5-day MTT assays. We 
observed that rosiglitazone alone had no effects on cell proliferation (data 
not shown). However, it actually prevented the growth inhibition that was 
induced by gefitinib in EGFR dependent cells (Figure 4.12). These data 
appeared to contradict previous studies, which concluded that PPARγ 
agonists inhibit proliferation and/or induce apoptosis in bladder cancer 
cells [166,167]. However, these previous studies used very high 
concentrations (≥ 100µM) of the PPARγ agonists compared to our study, 
and we concluded that rosiglitazone had no effects on cell proliferation by 
itself in any of the cell lines at concentrations that induced strong FABP4 
expression. Furthermore, stable FABP4 knockdown (gene knockdown 
efficacy shown in figure 4.13 lower panel) blocked the gefitinib resistance 
induced by rosiglitazone in the EGFR dependent cell lines (UM-UC4, UM- 
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Figure 4.12 Activation of the PPARγ signaling pathway blocks EGFR 
dependency. The EGFR-dependent UM-UC4, UM-UC5, UM-UC7, and 
UM-UC9 cells were exposed to rosiglitazone (1μM), gefitinib (1μM), or a 
combination of both (1μM each) at days 0 and 2, and cell proliferation was 
measured at day 5 using MTT assays. Data are normalized to controls 
and indicated as means ± SEM. 
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Figure 4.13 Efficiency of FABP4 silencing in FGFR dependent (UM-
UC14 and RT4) and EGFR dependent (UM-UC5 and UM-UC9) cells. 
Cells were transfected with FABP4 shRNA constructs (C6 or D4) along in 
FGFR dependent cells or in the presence of absence of PPARγ agonist 
rosiglitazone in the EGFR dependent cells. FABP4 mRNA expression was 
measured by quantitative PCR.  
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UC5, UM-UC7 and UM-UC9) (Figure 4.14). Specifically, rosiglitazone 
induced resistance to gefitinib in these EGFR dependent cells (Figure 
4.12). However, exposure to rosiglitazone didn’t prevent growth inhibition 
induced by gefitinib when FABP4 was stably silenced (Figure 4.14). 
Given that our data suggested induction of FABP4 expression promoted 
resistance to gefitinib in EGFR dependent cells, it is presently unclear 
whether FABP4 modulation altered sensitivity to EGFR inhibitor gefitinib in 
FGFR dependent cells. Therefore, we first stably knocked down FABP4 in 
FGFR dependent cell lines UM-UC14 and RT4. Gene silencing efficacy 
was measured by PCR analysis (Figure 4.13 upper panel). We then 
exposed the stable FABP4-knockdown UM-UC14 and RT4 with gefitinib to 
test whether decreased FABP4 increased sensitivity to gefitinib. Cell 
growth data revealed that FABP4 silencing induced concentration 
dependent response to gefitinib in FGFR dependent cells UM-UC14 and 
RT4, whereas the counterpart NT controls remained resistance to gefitinib 
(Figure 4.15). Overall, we could conclude that sensitivity to EGFR inhibitor 
gefitinib could be affected by PPARγ activation, specifically modulation of 
FABP4. 
4.1.5. CHOP acts downstream of PPARγ (Preliminary data) 
To identify the downstream transcriptional targets of PPARγ that 
controlled EGFR dependency, we performed whole genome gene 
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Figure 4.14 FABP4 silencing blocks rosiglitazone-induced gefitinib 
resistance.  EGFR dependent cells (UM-UC4, UM-UC5, UM-UC7, and 
UM-UC9) were stably transduced with the FABP4-specific or non-targeting 
shRNA constructs.  Cells were then exposed to rosiglitazone (1μM), 
gefitinib (1μM), or a combination of both (1μM each) for 5 days, and cell 
proliferation was measured using MTT assays. Data were normalized to 
NT controls and indicated as mean ± SEM. 
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Figure 4.15 Down-regulation of FABP4 promotes gefitinib sensitivity 
in FGFR-dependent cells. UM-UC14 and RT4 were stably transduced 
with two different FGFR3-specific lentiviral shRNA constructs (C6 or D4) 
or a non-targeting (NT) control.  Cells were then exposed to the indicated 
concentrations of either AZD4547 or gefitinib, and cell proliferation was 
measured after 48 hours using thymidine incorporation assays. Data were 
normalized to NT control and indicated as mean ± SEM. 
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expression profiling of the EGFR dependent UM-UC9 cells incubated with 
or without rosiglitazone (in triplicate). We also performed the gene 
expression profiling of the FGFR dependent UM-UC14 cells transduced 
with non-targeting or FABP4-specific shRNA constructs (in triplicate). We 
then performed class comparison analyses using BRB Array Tools to 
extract the significantly differentially expressed genes in each cell line 
group (p<0.001 with FDR <0.1) and subjected the genes to Ingenuity 
Pathway Analyses (IPA). These analyses identified the known PPARγ 
target FABP4 as one of top 5 activated genes in the rosiglitazone-treated 
UM-UC9 cells and one of top 5 suppressed genes in the FABP4 silenced 
UM-UC14 cells, which was expected and served as a positive control.  
Other than FABP4, the endoplasmic reticular (ER) stress-responsive 
transcription factor GADD153/CHOP (DDIT3) was the only other gene that 
was shared among the top 5 altered genes in both models (Table 4.1). 
Furthermore, using the IPA Upstream Regulators function, the CHOP 
pathway was identified as the one that was most strongly down-regulated 
in the FABP4 silenced UM-UC14 cells and most strongly up-regulated 
pathway in the rosiglitazone-treated UM-UC9 cells. In addition, 4 out of 4 
CHOP targeted molecules defined by IPA changed in the same direction 
as CHOP did in FABP4 silenced UM-UC14 cells (Figure 16 left panel). 
Among these 4 genes, GADD34, ERO1L also changed in the same 
direction as CHOP did in rosiglitazone-treated UM-UC9 cells (Figure 16 
right panel). Interestingly, the cyclic AMP-dependent transcription factor  
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Table 4.1 Identification of GADD153/CHOP/DDIT3 as a PPARγ target 
gene. List of differentially expressed genes that were shared in FABP4 
knockdown UM-UC14 cells compared to non-targeting (NT) controls, and 
rosiglitazone-treated UM-UC9 cells versus controls. 
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Figure 4.16 Identification of GADD153/CHOP/DDIT3 as a PPARγ 
target gene. Heatmap depicts CHOP (DDIT3) expression and expression 
of its IPA-defined downstream targets (HSPE1, CASP4, ERO1L, 
GADD34, LCN2) in the UM-UC14 and UM-UC9 experimental sets. 
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ATF-3 (ATF3), which acts downstream of CHOP, was also among the top 
IPA “upstream regulators” as measured by log ratio change in both 
subsets (data not shown). 
 
4.2. Discussion 
Previous work has revealed the existence of subsets of human bladder 
cancer cells that are either EGFR [115,147] or FGFR3 [70,156] dependent 
for cell proliferation and tumor growth. However, little is known regarding 
the underlying mechanism of such EGFR or FGFR3 dependency in 
human urothelial cancer cells. Although recent studies have provided 
some indirect explanation, including pathway redundancy and impaired 
negative feedback loops [132], much is left to be discovered. In this study, 
we directly demonstrated for the first time that EGFR and FGFR3 
dependency are non-overlapping and mutually exclusive in human 
urothelial cancer. Furthermore, our data suggested that this mutually 
exclusive EGFR or FGFR3 dependency is tightly regulated by PPARγ 
signaling both in human urothelial cancer cells and in orthotopic xenograft. 
PPARγ, a member of peroxisome proliferator activated receptors active in 
nucleus, is a intracellular transcription factor well known for its important 
role in adipogenesis and tissue differentiation [168-171]. On the other 
hand, CHOP is also a transcription factor that is extensively studied for its 
role in the response to ER stress [172]. Although their roles in controlling 
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of growth factor receptor dependency in human cancer have not been 
reported, previously a few studies have demonstrated that C/EBP protein 
family acts as co-activators with PPARγ to promote the transcription of 
genes involved in adipogenesis and adiopocyte differentiation 
[169,171,173]. A recent chromatin immunoprecipitaiton sequencing study 
revealed that C/EBP binding motifs were located in the vicinity of PPAR 
binding site, and both C/EBP proteins and PPARγ binding to specific DNA 
motifs were required for robust adipocyte gene expression. Collectively, 
our data suggested for the first time that PPARγ potentially coordinate with 
CHOP to control EGFR dependency. To verify this hypothesis that CHOP 
acts downstream of PPARγ to regulate EGFR sensitivity, we are planning 
to directly silence CHOP in UM-UC14 and RT4 and test whether silencing 
of CHOP sensitize these cells to EGFR antagonist gefitinib. Moreover, we 
also planning to overexpress CHOP in original EGFR dependent cells 
(UM-UC4, UM-UC5, UM-UC7 and UM-UC9) and test whether activation of 
PPARγ by overexpression of CHOP will block the sensitivity to EGFR 
inhibitor gefitinib. If our hypothesis is tested to be true, we are going to 
further investigate whether PPARγ-CHOP signaling regulate EGFR 
dependency through mechanisms that directly interact with the receptor. 
Previous work suggested that pathway redundancy provided escape 
mechanisms for acquired resistance to EGFR TKIs [132,145], which 
indicated a direct interaction between EGFR and FGFR on the receptor 
level. Furthermore, given the high level of downstream signal transduction 
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redundancy between EGFR and FGFR3 signaling [115,156], it is possible 
that PPARγ signaling employs mechanisms that directly interact with the 
respective receptors rather than with downstream signaling components to 
modulate EGFR or FGFR3 dependency.  MIG6, one of the four EGFR 
inducible feedback inhibitors, is a cytosolic protein that is induced through 
EGFR activation and attenuates EGFR signaling following its activation 
[174]. MIG6 contains a centrally located ErbB binding region (ERB) that 
allows for specific binding to EGFR kinase domain to lock EGFR 
molecules in a catalytically inactive configuration, which prevents signal 
generation and transduction [174]. Moreover, MIG6 also has the capability 
to rapidly down-regulate EGFR molecules and route them to lysosome for 
degradation [175,176]. Overexpression of MIG6 is sufficient to abrogate 
EGFR phosphorylation and activation, EGFR mediated downstream 
signaling transduction, and EGFR regulated biological and cellular 
function [174,177]. Given that, we are planning to directly test the 
hypothesis that MIG6 (ERRFI1 or RALT) acts as a downstream target of 
PPARγ signaling to inhibit EGFR dependency though MIG6’s direct 
interaction between MIG6 and respective receptors without interfering with 
the downstream MAPK/Erk and PI3K pathways, which are also used to 
mediate FGFR3 dependency. 
While our data revealed that PPARγ-CHOP signaling modulated EGFR 
dependency, it is still unclear whether PPARγ-CHOP controls FGFR3 
dependency. Therefore, we are planning to examine the linkage between 
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PPARγ-CHOP and FGFR3 dependency. Although preliminary data 
suggested that rosiglitazone alone did not increase sensitivity to the FGFR 
inhibitor AZD4547 in EGFR dependent cell line UM-UC9 (data not shown), 
it was possible that FGFR3 dependency required high level expression of 
surface FGFR3, which was evidenced by our previous study [70,156]. 
Hence, we are going to direct test this hypothesis using exogenous 
expression of FGFR3 in UM-UC9. Moreover, we are also planning to 
examine whether PPARγ-CHOP controls FGFR3 dependency in cells 
natively responding to FGFR3 inhibitors. 
FGFR substrate 2α (FRS2) is a docking/scaffolding adaptor protein that 
functions downstream of certain receptor tyrosine kinases to promote 
signal transduction [178]. Specifically, emerging evidence indicated that 
FRS2α acts as a control center for FGFR intracellular signaling. It 
becomes tyrosine phosphorylation on several residues followed by FGFR 
activation, which creates binding sites for SH2 domain of Grb2 adaptor 
protein. The activated Grb2 recruits multiple adaptor proteins including 
SOS that finally leads to strong activation of Ras/MAPK/Erk pathway 
[179]. Interestingly and more importantly, FRS2α selectively binds some 
receptor tyrosine kinases over the others, which is one of the unique 
characters of this adaptor protein [178]. A good example is that It acts 
downstream of FGFRs but not EGFR. Therefore, we could further 
hypothesize that PPARγ-CHOP signaling controls FGFR3 dependency via 
the induction of FRS2α without interfering with EGFR-mediated signaling, 
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and we are going to test it using exogenous expression of CHOP in UM-
UC9 cells. Furthermore, exploring the link between PPARγ-CHOP and 
FRS2α would provide direct mechanistic explanation as to why PPARγ-
CHOP regulates FGFR3 dependency. 
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CHAPTER 5. FINAL CONCLUSIONS AND FUTURE 
DIRECTIONS 
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5.1. Final conclusions 
5.1.1. FGFR3 regulates human urothelial cancer growth 
In summary, we have demonstrated that the levels of FGFR3 expression 
correlate with FGFR3 dependency, and that FGFR3 is more important 
than FGFR1 in driving proliferation in human urothelial cancer cells. 
Specifically, FGFR3 expression correlated well with the sensitivity to the 
FGFR antagonist (BGJ-398) in a panel of 17 urothelial cancer cell lines. 
Furthermore, silencing of FGFR3 simulates the effects of BGJ-398 
exposure in both UM-UC14 and RT4 cells in vitro. Additionally, both 
exposure to BGJ-398 and FGFR3 specific knockdown using an RNAi 
based strategy produced cell cycle arrest, which indicate that FGFR 
inhibitors induce cytostatic but not cytotoxic in human bladder cancer 
cells. Our data together with other recent studies [102,154,156] support 
the ongoing development of FGFR specific inhibitors for clinical targeted 
therapy, particularly in combination with chemotherapy or radiation 
therapy due to their cytostatic effects. However, human urothelial cancer 
cells display a remarkable heterogeneity in sensitivity to FGFR inhibitors 
as revealed both in this study and previous work [156]. It is still unclear 
what mechanisms drive the intrinsic sensitivity to FGFR inhibitors, though 
several mechanisms have been proposed including FGFR3 activating 
mutations, the presence of TACC3-FGFR3 translocation, and high level of 
FGFR3 expression. The predictive value of these markers must now be 
determined in urothelial cancer patients so that it is practically possible to 
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identify the appropriate subset of bladder cancer patients who could 
benefit markedly from the FGFR targeted therapy. Therefore, tremendous 
efforts from clinical research are needed in the future to uncover the 
mechanisms that could lead to successful development of biomarkers to 
identify the patient population for FGFR3 targeted therapy. 
5.1.2. FGFR1 mediates human urothelial cancer metastasis 
More importantly, our study indicates that FGFR1 mediates cell invasion 
and tumor metastasis in human urothelial cancer. Specifically, FGFR1 
repression by either FGFR antagonist (BGJ-398) or direct FGFR1 
silencing severely reduced cell invasion in vitro. In addition, exposure to 
BGJ-398 inhibited metastasis and circulating tumor cells production 
without affecting primary tumor growth in orthotopic tumor xenografts. 
Consistent with our conclusion, a recent study also supports the role of 
FGFR1 in promoting epithelial-to-mesenchymal transition, which results in 
increased levels of invasion and metastasis [104]. Although the same 
study suggested that FGFR1 promotes cell migration and invasion through 
cyclooxygenase-2 (COX-2) activation, much more is left to be determined. 
Further investigation utilizing global gene expression profiling and pathway 
analysis would be performed to address the cause-effect questions of 
what signaling pathways and transcriptional factors acting downstream of 
FGFR1 to promote cell invasion and tumor metastasis. Furthermore, our 
study also provides a rationale for targeting FGFR, specifically FGFR1, to 
prevent invasion and treat metastasis. Clinically, ~20% of the non-muscle 
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invasive bladder cancers progress to become muscle invasive and 
metastatic, which accounts for the bulk of patient mortality. If appropriate 
biomarkers could be developed to identify the right patient subset, FGFR1 
targeted therapy combined with conventional chemotherapy could be 
beneficial to this sub-group of patients. Therefore, future effects should 
focus on the development of clinically relevant biomarkers to prospectively 
identify patients who are more likely to benefit from FGFR targeted 
therapy as well as testing the efficacy of FGFR targeted therapy in a 
metastatic setting. 
5.1.3. Heterogeneous sensitivity to FGFR antagonist in “epithelial” 
bladder cells 
Finally, our study suggests that there is profound heterogeneity of FGFR3 
dependency. Specifically, although some of the urothelial cell lines that 
contain activating mutations were highly sensitive to FGFR inhibitors, the 
majority of FGFR3-mutant cell lines remained resistant to FGFR inhibitor 
(BGJ-398). Previously, several studies have uncovered the mechanisms 
how FGFR3 activating mutations drive proliferation in human bladder 
cancer cells. However, our data suggest the existence of more 
complicated biological interaction that urothelial cells possess, which 
require further investigate to elucidate and validate. Recently, several 
studies highlight the EGFR and FGFR interaction as one of the 
mechanisms that cells escape from the pressure of FGFR antagonist, 
which provide a direction to elucidate the mechanism of intrinsic and 
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acquired resistance. We plan to further investigate the FGFR3-mutant cell 
lines that are resistant to FGFR inhibitor to uncover the escape 
mechanisms, with hopes of identifying the best strategies to appropriately 
utilize FGFR targeted therapy to benefit patient clinically.  
5.1.4. Discrete EGFR dependency is controlled by PPARγ-FABP4 
transcriptional complex 
We demonstrate for the first time that EGFR and FGFR3 dependency are 
non-overlapping and mutually exclusive to each other in human urothelial 
cancer. More specifically, we have identified 4 cell lines (UM-UC4, UM-
UC5, UM-UC7 and UM-UC9) that were sensitive to EGFR antagonist 
gefitinib but not to FGFR antagonist AZD4547 at the clinical relevant 
concentration (≤ 1μM). We also identify different 4 cell lines (UM-UC14, 
SW780, RT4 and RT112) that were sensitive to FGFR inhibitor AZD4547 
but not to EGFR inhibitor gefitinib. Our data indicated the possibility that 
human urothelial cancer cells depends primarily on one single growth 
factor receptor for growth and proliferation. However, this idea needs 
extensive research to test and validate.  
Furthermore, the observation that PPARγ signaling pathway controls this 
mutually exclusive biological phenotype extends our knowledge of 
molecular mechanism that mediates EGFR dependent proliferation. More 
specifically, PPARγ signal activation is enriched in FGFR3 dependent (but 
EGFR inhibitor resistant) urothelial cells, whereas EGFR dependent (but 
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FGFR inhibitor resistant) urothelilal cells lack PPARγ activation. In 
addition, up-regulation of FABP4 forces EGFR dependent cells becoming 
resistance to EGFR antagonist while down-regulation of FABP4 promotes 
sensitivity to EGFR inhibitor in FGFR3 dependent cells. Overall, we for the 
first time have shown that PPARγ activation, specifically via FABP4, 
represses EGFR dependency that is exclusive to FGFR3 dependency in 
urothelilal cancer. 
 
5.2. Future directions 
5.2.1. FGFR1 and cell invasion 
In this study, we have demonstrated that FGFR1 inhibition blocks cell 
invasion and tumor metastasis. More specifically, direct FGFR1 silencing 
decreased cell invasion in vitro, and the FGFR antagonist BGJ-398 
reduced tumor metastasis in orthotopic UM-UC3 metastatic xenografts in 
vivo. However, these interesting findings present at least two important 
avenues that require further research and elucidation. First, our data 
suggests that FGFR1 but not FGFR3 is responsible for cell invasion in 
“mesenchymal” UM-UC3 and UM-UC13 cells. However, our in vivo data 
don’t necessarily show that FGFR1 but not FGFR -2 or -3 regulated tumor 
metastasis because we used BGJ-398, a pan FGFR1-3 antagonist, 
instead of a direct FGFR1 inhibitor to conduct the animal study. Given the 
similarity of protein sequence among FGFRs, it is very difficult to develop 
124 
 
a specific FGFR1 antagonist. However, we could resolve this problem 
using FGFR1 gene silencing. Specifically, we could conduct a three arm in 
vivo study to directly test the hypothesis, with one arm for wild-type 
metastatic UM-UC3, the second arm transduced with non-targeting 
scramble shRNA, and the third arm transduced with FGFR1 specific 
shRNA. 
Secondly, our study and a recent publication [104] suggest the role of 
FGFR1 in cell invasion and possible epithelial-to-mesenchymal transition. 
However, it is presently unclear that how FGFR1 regulates cell invasion, 
what molecules act downstream of FGFR1 pathway to mediate cell 
invasion and whether such a regulation involves EMT. To address these 
questions, we could start with gene expression profiling study to identify 
differential expressed genes by directly comparing the expression profile 
between non-targeting and FGFR1 knockdown in UM-UC3 and UM-UC13. 
Following upon the identification of differential expressed genes, we could 
use Ingenuity Pathway Analysis to dissect differential expressed genes to 
pinpoints candidates for further investigation. Finally, we could test the 
hypothesis that the candidate genes acts downstream of FGFR1 and are 
directly responsible for cell invasion and/or epithelial-to-mesenchymal 
transition. 
 
125 
 
5.2.2. Discrete EGFR dependency and PPARγ-FABP4 axis 
In this study, we have identified the non-overlapping and mutually 
exclusive FGFR3 and EGFR dependency in urothelial cancer cells. The 
observation prompts us to propose the hypothesis that urothelial cancer 
cells or even cancer cells in genenral depends primarily on one single 
growth factor receptor for cell proliferation and tumor growth [180]. 
Therefore, we are going to evaluate various TKIs in vitro for their effects 
on proliferation of human urothelial cancer cells with the purpose to 
identify cell lines that are dependent on one primary growth factor receptor 
other than pre-defined EGFR and FGFR3 dependent cells in this study. 
The proposed study would elucidate the tendency whether one primary 
growth factor receptor drives proliferation in given cancer cells, which 
would pave the way to investigate and develop molecular signatures that 
would be ultimately used in clinic to improve personalized medicine. 
Furthermore, it will be helpful to investigate the molecular mechanism of 
such a dependency in order to identify relevant biomarkers/signatures for 
clinical translation. Given that the downstream signal transduction 
pathways controlled by the growth factor receptors are highly redundant, it 
is more likely that the molecular signatures that are responsible for such 
dependency lie in genes mediating growth factor receptor internalization, 
cytoplasmic trafficking, or controlling negative feedback loop mechanism. 
We plan to utilize genomic wide gene expression profiling to directly test 
these hypotheses. Presently, multiple studies have suggested the role of 
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pathway redundancy as one of the mechanisms cells employing to escape 
from TKIs. With this context in mind, we are going to directly examine the 
hypothesis that activating alternative growth factor receptors contributes to 
the resistance to FGFR or EGFR inhibition, which could help us to 
understand the mechanisms of intrinsic or acquired resistance. 
Additionally, we demonstrate that the PPARγ signaling regulates the 
EGFR dependency. These important findings present at least two 
opportunities upon further experimental examination and validation. 
Firstly, we have established throughout our study that PPARγ signaling 
promotes CHOP expression in EGFR dependent urothelial cancer cells. 
However, our data does not provide details with respect to how PPARγ 
interacts with FABP4 to stimulate CHOP expression. Previously, FABP4 
was shown to function as a specific co-activator for PPARγ through “ligand 
tunneling”, which facilitates PPARγ ligands transferring and binding to 
PPARγ receptor, and then promotes PPARγ translocation to nucleus. To 
specific address this question, we plan to investigate the PPARγ-FABP4 
protein to protein interaction in FGFR3 dependent cells, examine the 
CHOP promoter area to identify potential PPARγ binding sites, and design 
chromatin immunoprecipitation (ChIP) experiment to confirm the binding of 
PPARγ-FABP4 complex to CHOP promoter. 
Secondly, we identified several potential signatures, including high level of 
FGFR3 expression, FGFR3 activating mutation, and activation of PPARγ 
signaling, in the FGFR3 dependent cells although we haven’t established 
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the cause-effect link between PPARγ activation and FGFR3 dependency. 
We would further investigate this hypothesis by testing whether 
modulation of PPARγ activation affects FGFR3 dependency. Furthermore, 
if the hypothesis could be proven true, these findings could pave the way 
for uncovering clinical biomarkers to prospectively identify appropriate 
subset of patients who could benefit from FGFR3 targeted therapy. 
However, further clinical research in a large scale is needed to verify the 
correlation between FGFR and PPARγ-FABP4 signaling, and obtain the 
biomarker profiling to support the prospective identification of patient 
subset. We would also direct test the predictive power of these presumed 
biomarkers (PPARγ, FABP4, FGFR3 and its mutation) in clinical trials that 
are primarily designed to testing selective FGFR inhibitors in patients. 
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